INVESTIGATING THE MOLECULAR MECHANISM OF
PHOSPHOLAMBAN REGULATION OF THE Ca\(^{2+}\)-PUMP
OF CARDIAC SARCOPLASMIC RETICULUM

Brandy Lee Akin

Submitted to the faculty of the University Graduate School
in partial fulfillment of the requirements
for the degree
Doctor of Philosophy
in the Department of Biochemistry and Molecular Biology,
Indiana University

December 2010
Accepted by the Faculty of Indiana University, in partial fulfillment of the requirements for the degree of Doctor of Philosophy.

Larry R. Jones, M.D., Ph.D., Chair

Loren J. Field, Ph.D.

Doctoral Committee

Andy Hudmon, Ph.D.

Thomas D. Hurley, Ph.D.

November 4, 2010

Peter J. Roach, Ph.D.
To

My Family
ACKNOWLEDGEMENTS

I am sincerely grateful to the chair of my research committee, Dr. Larry Jones, for his guidance, encouragement, and patience during my dissertation studies. I could not have had a better mentor. I am also grateful to the other members of my research committee: Dr. Peter Roach, Dr. Tom Hurley, Dr. Andy Hudmon, and Dr. Loren Field, for their guidance and expertise. Finally, I would like to thank my husband Jon and our children Adelaide and Jonathan for always being there for me. You inspire and motivate me every day of my life. Thank you.
ABSTRACT

Brandy Lee Akin

INVESTIGATING THE MOLECULAR MECHANISM OF PHOSPHOLAMBAN REGULATION OF THE Ca2+-PUMP OF CARDIAC SARCOPLASMIC RETICULUM

The Ca2+ pump or Ca2+-ATPase of cardiac sarcoplasmic reticulum, SERCA2a, is regulated by phospholamban (PLB), a small inhibitory phosphoprotein that decreases the apparent Ca2+ affinity of the enzyme. We propose that PLB decreases Ca2+ affinity by stabilizing the Ca2+-free, E2·ATP state of the enzyme, thus blocking the transition to E1, the high Ca2+ affinity state required for Ca2+ binding and ATP hydrolysis. The purpose of this dissertation research is to critically evaluate this idea using series of cross-linkable PLB mutants of increasing inhibitory strength (N30C-PLB < PLB3 < PLB4). Three hypotheses were tested; each specifically designed to address a fundamental point in the mechanism of PLB action.

Hypothesis 1: SERCA2a with PLB bound is catalytically inactive. The catalytic activity of SERCA2a irreversibly cross-linked to PLB (PLB/SER) was assessed. Ca2+-ATPase activity, and formation of the phosphorylated intermediates were all completely inhibited. Thus, PLB/SER is entirely catalytically inactive.

Hypothesis 2: PLB decreases the Ca2+ affinity of SERCA2a by competing with Ca2+ for binding to SERCA2a. The functional effects of N30C-PLB, PLB3, and PLB4 on Ca2+-ATPase activity and phosphoenzyme formation were measured, and correlated with their binding interactions with SERCA2a measured by chemical cross-linking. Successively higher Ca2+ concentrations were required to both activate
the enzyme co-expressed with N30C-PLB, PLB3, and PLB4 and to dissociate N30C-
PLB, PLB3, and PLB4 from SERCA2a, suggesting competition between PLB and
Ca$^{2+}$ for binding to SERCA2a. This was confirmed with the Ca$^{2+}$ pump mutant,
D351A, which is catalytically inactive but retains strong Ca$^{2+}$ binding. Increasingly
higher Ca$^{2+}$ concentrations were also required to dissociate N30C-PLB, PLB3, and
PLB4 from D351A, demonstrating directly that PLB competes with Ca$^{2+}$ for binding
to the Ca$^{2+}$ pump.

Hypothesis 3: PLB binds exclusively to the Ca$^{2+}$-free E2 state with bound
nucleotide (E2·ATP). Thapsigargin, vanadate, and nucleotide effects on PLB cross-
linking to SERCA2a were determined. All three PLB mutants bound preferentially to
E2 state with bound nucleotide (E2·ATP), and not at all to the thapsigargin or
vanadate bound states.

We conclude that PLB inhibits SERCA2a activity by stabilizing a unique
E2·ATP conformation that cannot bind Ca$^{2+}$.

Larry R. Jones, M.D., Ph.D., Chair
TABLE OF CONTENTS

LIST OF TABLES ......................................................................................................................... x
LIST OF FIGURES ...................................................................................................................... xi
ABBREVIATIONS ........................................................................................................................ xiii

CHAPTER 1—INTRODUCTION ...................................................................................................... 1
A. Excitation-contraction coupling in cardiac myocytes .............................................................. 1
B. Regulation of PLB by the β-adrenergic signaling pathway ....................................................... 3
C. The β-adrenergic pathway and heart failure ........................................................................... 5
D. The mechanism of Ca$^{2+}$ transport by SERCA2a ................................................................. 6
E. PLB structure and function ..................................................................................................... 9
F. Developing a model of PLB regulation of SERCA2a using chemical cross-linking .................. 11
G. Purpose ...................................................................................................................................... 19
   1. Hypothesis 1: SERCA2a with PLB bound is catalytically inactive ......................................... 20
      a. Testing the catalytic activity of SERCA2a with PLB bound ................................................. 20
   2. Hypothesis 2: PLB decreases the Ca$^{2+}$ affinity of SERCA2a by competing with Ca$^{2+}$ for binding to the enzyme ................................................................. 21
      a. Using cross-linkable PLB supershifters to test for competitive binding of PLB and Ca$^{2+}$ to SERCA2a ................................................................. 22
      b. Using PLB supershifters in conjunction with D351A-SERCA2a to test for competitive binding of PLB and Ca$^{2+}$ to SERCA2a ................................................................. 23
      c. Determining the effect of PLB on maximal Ca$^{2+}$-ATPase activity ........................................ 24
   3. Hypothesis 3: PLB binds exclusively to the $E_2\cdot$ATP conformation of the Ca$^{2+}$ pump ................................................................. 25
      a. Investigating the conformational specificity of the PLB to SERCA2a binding interaction using the effectors TG, vanadate, and nucleotides (ATP, ADP, and AMP) ................................................................. 25

CHAPTER 2—EXPERIMENTAL PROCEDURES ............................................................................ 26
A. Materials .................................................................................................................................... 26
B. Mutagenesis and baculovirus production...............................................................26
C. Protein expression and characterization.................................................................26
D. Ca\(^{2+}\)-ATPase assay........................................................................................27
E. Cross-linking PLB to SERCA2a .........................................................................28
   1. Standard Cross-linking (small scale) ..........................................................28
   2. Large scale cross-linking ............................................................................28
   3. Cross-linking under Ca\(^{2+}\)-ATPase conditions.......................................29
F. Monitoring formation of the phosphorylated intermediates, \(E_1\)~P and \(E_2\)~P........30
   1. Phosphorylation of \(E_1\cdot\text{Ca}_2\) by \([\gamma\text{-}32\text{P}]\text{ATP}\) .................................................30
   2. Phosphorylation of \(E_2\) by \(32\text{P}_1\) (back door phosphorylation)...30

CHAPTER 3—RESULTS.........................................................................................31
A. Hypothesis 1: SERCA2a with PLB bound is catalytically inactive...............31
   1. Large scale pre-cross-linking of N30C-PLB to SERCA2a.........................31
   2. Phosphorylation of pre-cross-linked membranes with \([\gamma\text{-}32\text{P}]\text{ATP}\) and
      \(32\text{P}_1\) to form \(E_1\)~P and \(E_2\)~P.................................................................32
   3. Resolution of PLB-free SERCA2a (catalytically active
      SERCA2a) from PLB/SER (catalytically inactive SERCA2a) .......................34
B. Hypothesis 2: PLB decreases the Ca\(^{2+}\) affinity of SERCA2a by competing
   with Ca\(^{2+}\) for binding to the enzyme..............................................................36
   1. Co-expression of SERCA2a with N30C-PLB, PLB3 and PLB4..............36
   2. Ca\(^{2+}\) activation of Ca\(^{2+}\)-ATPase activity and Ca\(^{2+}\) inhibition of PLB
      cross-linking to SERCA2a............................................................................37
   3. Ca\(^{2+}\) stimulation of \(E_1\)~P formation correlated with Ca\(^{2+}\) inhibition
      of PLB cross-linking to SERCA2a .............................................................41
   4. The effect of 2D12 on Ca\(^{2+}\)-ATPase activity and PLB cross-linking........41
   5. The effect of Ca\(^{2+}\) on PLB cross-linking to D351A.................................43
C. Hypothesis 3: PLB binds exclusively to the \(E_2\cdot\text{ATP}\) conformation of the
   Ca\(^{2+}\) pump....................................................................................................46
   1. The effect of TG and nucleotides on PLB cross-linking to WT-
      SERCA2a pump.........................................................................................46
2. The effects of TG and nucleotides on PLB cross-linking to D351A-SERCA2a

3. The effects of vanadate on PLB cross-linking to SERCA2a

CHAPTER 4—DISCUSSION

A. Hypothesis 1: SERCA2a with PLB bound is catalytically inactive

B. Hypothesis 2: PLB decreases the Ca\(^{2+}\) affinity of SERCA2a by competing with Ca\(^{2+}\) for binding to the enzyme

1. PLB supershifters reveal competitive binding of PLB and Ca\(^{2+}\) to SERCA2a

2. Confirming competitive binding of PLB and Ca\(^{2+}\) to SERCA2a using catalytically inactive D351A

3. The effects of PLB on the \(V_{\text{max}}\) of SERCA2a

4. The physiological effects of PLB

5. Structural considerations: long distance communication between the Ca\(^{2+}\) binding sites and the catalytic site

C. Hypothesis 3: PLB binds exclusively to the E2·ATP conformation of the Ca\(^{2+}\) pump

1. PLB binds to deprotonated E2·ATP

2. The affinity of PLB for SERCA2a

D. Conclusions and future directions

REFERENCES

CURRICULUM VITAE
LIST OF TABLES

Table 1. $K_{Ca}$ values ($\mu$M) for Ca$^{2+}$-ATPase activation and $E1\sim P$ formation, and $K_i$ values ($\mu$M) for Ca$^{2+}$ inhibition of PLB cross-linking............37

Table 2. $K_{TG}$ values ($\mu$M) for TG inhibition of PLB cross-linking to the Ca$^{2+}$-ATPase .................................................................46

Table 3. $K_{ATP}$ values ($\mu$M) for ATP stimulation of PLB4 cross-linking to the Ca$^{2+}$-ATPase, determined at different TG concentrations........49
**LIST OF FIGURES**

<table>
<thead>
<tr>
<th>Figure</th>
<th>Description</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Excitation-Contraction Coupling and Ca(^{2+}) Cycling in Cardiac Myocytes</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>Effect of the Catalytic Subunit of PKA (CSU) and the Anti-PLB monoclonal</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Antibody (2D12) on Ca(^{2+})-Uptake by Guinea Pig Ventricular SR Vesicles</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Crystal Structures of the (E_2) and (E_1) Conformations of SERCA</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>Reaction Cycle of SERCA2a</td>
<td>8</td>
</tr>
<tr>
<td>5</td>
<td>Amino Acid Sequence of PLB</td>
<td>9</td>
</tr>
<tr>
<td>6</td>
<td>Structural Model for the Interaction Between PLB and SERCA2a</td>
<td>11</td>
</tr>
<tr>
<td>7</td>
<td>Sites of PLB Cross-linking to SERCA2a with Homo- and Hetero-bifunctional</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>Cross-linkers</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>Ca(^{2+}) Inhibition of Cross-linking of Residues 45-52 of PLB to V89C-</td>
<td>13</td>
</tr>
<tr>
<td></td>
<td>SERCA2a</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>Effect of Ca(^{2+}) on Cross-linking of N30C-PLB to SERCA2a with BMH</td>
<td>14</td>
</tr>
<tr>
<td>10</td>
<td>Ca(^{2+}) Effect on Cross-linking of Phosphorylated and Dephosphorylated</td>
<td>14</td>
</tr>
<tr>
<td></td>
<td>PLB to SERCA2a</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>ATP Dependence of PLB Cross-Linking</td>
<td>15</td>
</tr>
<tr>
<td>12</td>
<td>ATP Concentration-Dependence on Cross-linking and (E_2)-P Formation</td>
<td>16</td>
</tr>
<tr>
<td>13</td>
<td>TG Inhibition of Cross-Linking of Residues 45-52 of PLB to V89C-SERCA2a</td>
<td>17</td>
</tr>
<tr>
<td>14</td>
<td>Our Model of PLB Regulation of SERCA2a Activity</td>
<td>18</td>
</tr>
<tr>
<td>15</td>
<td>Complete Amino Acid Sequences of the Cross-linkable PLB</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>Mutants,N30C-PLB, PLB3, and PLB4</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Effect of PLB Cross-linking to SERCA2a on Maximal Ca(^{2+})-ATPase Activity</td>
<td>32</td>
</tr>
<tr>
<td>17</td>
<td>Effect of PLB Cross-Linking to SERCA2a on Maximal (E_1)-P and (E_2)-P</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Formation</td>
<td></td>
</tr>
</tbody>
</table>
Figure 18. Phosphorylation of Pre-Cross-Linked Membranes and LDS-PAGE Resolution of PLB-free SERCA2a from PLB/SER ..........35
Figure 19. Amido Black Staining and Immunoblot of SERCA2a Co-Expressed with N30C-PLB, PLB3, and PLB4 .........................36
Figure 20. Ca$^{2+}$ activation of Ca$^{2+}$-ATPase Activity and Ca$^{2+}$ Inhibition of Cross-linking ..........................................................39
Figure 21. PLB Effect on Formation of the Phosphorylated Enzyme Intermediate ........................................................................40
Figure 22. Effect of 2D12 on Ca$^{2+}$-ATPase activity and PLB cross-linking to SERCA2 .................................................................42
Figure 23. Ca$^{2+}$ effect on PLB cross-linking to D351A .........................44
Figure 24. TG effect on PLB cross-linking ..............................................47
Figure 25. Nucleotide Effect on PLB4 Cross-Linking to Wild-Type SERCA2a and D351A .................................................................48
Figure 26. Vanadate Effect on PLB Cross-Linking to SERCA2a ............50
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>SR</td>
<td>sarcoplasmic reticulum</td>
</tr>
<tr>
<td>PLB</td>
<td>phospholamban</td>
</tr>
<tr>
<td>SERCA</td>
<td>sarco(endo)plasmic reticulum Ca(^{2+})-ATPase</td>
</tr>
<tr>
<td>SERCA1a</td>
<td>isoform of Ca(^{2+})-ATPase in fast twitch skeletal muscle</td>
</tr>
<tr>
<td>SERCA2a</td>
<td>isoform of Ca(^{2+})-ATPase in cardiac SR</td>
</tr>
<tr>
<td>2D12</td>
<td>anti-PLB monoclonal antibody</td>
</tr>
<tr>
<td>MOPS</td>
<td>3-(N-morpholino)propanesulfonic acid</td>
</tr>
<tr>
<td>M</td>
<td>transmembrane domain</td>
</tr>
<tr>
<td>E1</td>
<td>high Ca(^{2+})-affinity conformation of Ca(^{2+})-ATPase</td>
</tr>
<tr>
<td>E2</td>
<td>low Ca(^{2+}) affinity conformation of Ca(^{2+})-ATPase</td>
</tr>
<tr>
<td>(K_{Ca})</td>
<td>Ca(^{2+}) concentration required for half-maximal effect</td>
</tr>
<tr>
<td>(K_i)</td>
<td>concentration giving half-maximal inhibition</td>
</tr>
<tr>
<td>KMUS</td>
<td>N-[maleimidoundecanoyloxy]sulfosuccinimide ester.</td>
</tr>
<tr>
<td>PKA</td>
<td>cAMP-dependent protein kinase</td>
</tr>
<tr>
<td>CaMKII</td>
<td>calmodulin kinase II</td>
</tr>
<tr>
<td>TG</td>
<td>thapsigargin</td>
</tr>
<tr>
<td>(P_i)</td>
<td>inorganic phosphate</td>
</tr>
<tr>
<td>(V_{max})</td>
<td>maximal velocity</td>
</tr>
</tbody>
</table>
CHAPTER 1—INTRODUCTION

A. EXCITATION-CONTRACTION COUPLING IN CARDIAC MYOCYTES

Ca\(^{2+}\) cycling through the SR of cardiac myocytes mediates contraction and relaxation of the heart (1). A contraction event is initiated when an electrical stimulus (action potential) originating from pacemaker cells in the sinoatrial node, arrives at the T-tubule of the cardiomyocyte, depolarizing the plasma membrane (sarcolemma). Membrane depolarization activates the voltage-dependent L-type Ca\(^{2+}\) channel also known as the dihydropyridine receptor (Fig. 1). Upon activation, the L-type Ca\(^{2+}\) channel permits small amount of extracellular “activator” Ca\(^{2+}\) to enter the cell. Then, through the process known as Ca\(^{2+}\) induced Ca\(^{2+}\) release, the “activator” Ca\(^{2+}\) triggers the opening of the Ca\(^{2+}\) release channels/ryanodine receptors in the membrane of the SR, and much of the intralumenal SR Ca\(^{2+}\) store is released into the cytoplasm (1). As cytosolic Ca\(^{2+}\) concentration increases to micromolar levels, Ca\(^{2+}\) ions bind to the troponin C subunit of the regulatory troponin complex, initiating a conformational change that relieves inhibition of the actin/myosin cross-bridge cycle, allowing myofilament contraction to occur (1). The mechanism by which the electrical signal (action potential) is converted into a mechanical response (myofilament contraction) is known as excitation-contraction coupling, a process fundamental to both cardiac and skeletal muscle.

Myofilament relaxation occurs when intracellular Ca\(^{2+}\) concentration is decreased to diastolic levels (nanomolar levels); Ca\(^{2+}\) is either removed from the cell by the plasma membrane Ca\(^{2+}\)-ATPase and the Na\(^+\)/Ca\(^{2+}\) exchanger, or pumped back into the lumen of the SR by the sarco(endo)plasmic reticulum Ca\(^{2+}\)-ATPase, SERCA2a. The majority of the intracellular Ca\(^{2+}\) (approximately 70%) is re-sequestered back into the lumen of the SR by the Ca\(^{2+}\) pump, SERCA2a, making Ca\(^{2+}\) available for the next contraction (1). Therefore, the rate of Ca\(^{2+}\) transport by SERCA2a determines both the rate of myofilament relaxation, and the size of the contractile-dependent SR Ca\(^{2+}\) store. Ca\(^{2+}\) pump activity is regulated by phospholamban (PLB), a small inhibitory phosphoprotein that acts as a molecular brake on enzyme activity (2, 3). Due to its essential role in maintaining Ca\(^{2+}\)
homeostasis in cardiac muscle cells, SERCA2a, and the mechanism by which SERCA2a activity is regulated by PLB is of great scientific and clinical interest. The overall purpose of this dissertation research was to investigate the molecular mechanism of PLB regulation of SERCA2a.

Figure 1. Excitation-Contraction Coupling and Ca\(^{2+}\) Cycling in Cardiac Myocytes  Simplified scheme depicting E-C coupling and SR Ca\(^{2+}\) cycling in cardiac ventricular myocytes. Membrane depolarization causes Ca\(^{2+}\) to enter the cell through the voltage-dependent sarcolemmal Ca\(^{2+}\) channel. This small influx in Ca\(^{2+}\) causes Ca\(^{2+}\) to be released from the SR by the ryanodine receptor (RYR), triggering myofilament contraction. Ca\(^{2+}\) is subsequently removed from the cytosol by the sarcolemmal Ca\(^{2+}\)-ATPase, the Na\(^+\)/Ca\(^{2+}\) exchanger, and by SERCA2a, the Ca\(^{2+}\)-ATPase in the SR membrane. Most of the cytosolic Ca\(^{2+}\) is re-sequestered into the lumen of the SR by SERCA2a, allowing myofilament relaxation to occur and making Ca\(^{2+}\) available for the next contraction. SERCA2a activity is modulated by the inhibitory phosphoprotein PLB. De-phosphorylated PLB inhibits Ca\(^{2+}\)-ATPase activity, and PKA phosphorylation of PLB reverses this inhibition. PKA activity is regulated via the β\(_1\)-adrenergic receptor signaling pathway. Catecholamine activation of the β-receptor results in G\(_S\)-mediated activation of adenylate cyclase (AC). AC converts ATP to cAMP, and activates PKA.
B. REGULATION OF PLB BY THE β-ADRENERGIC SIGNALING PATHWAY

In response to physical or psychological stress, cardiac output (the volume of blood pumped per unit time) by human hearts is increased within seconds, and the percentage increase in cardiac output above that required under resting conditions is defined as the cardiac reserve (1-3). The rate and strength of myocardial contraction and relaxation is regulated through the β-adrenergic signaling pathway (1-3). When an individual becomes stressed, epinephrine is released into the blood stream by the sympathetic nervous system, activating β-adrenergic receptors in the plasma membrane of cardiac myocytes (Fig. 1). The β-receptor is a G-protein coupled-receptor, which when stimulated activates a hetero-trimeric G-protein complex. The stimulatory Gsα subunit dissociates from the G-protein complex and activates adenylate cyclase. Adenylate cyclase converts ATP to cAMP, increasing the concentration of cAMP in the cell, and activating cAMP-dependent protein kinase (PKA) (Fig. 1). In response to β-adrenergic stimulation, PKA phosphorylates several downstream targets including the L-type Ca2+ channel, troponin I, and PLB (3). PKA phosphorylation of the sarcolemmal Ca2+ channel permits a greater influx of extracellular Ca2+ across the plasma membrane (2). PKA phosphorylation of troponin I, a subunit of the regulatory troponin complex, decreasing the affinity of troponin C for Ca2+, allowing for weaker myofilament contraction to occur at lower ionized Ca2+ concentrations (2). Phosphorylation of PLB by PKA (or calmodulin kinase II (CaMKII), see below) reverses PLB inhibition of SERCA2a, increasing the apparent Ca2+ affinity of the enzyme and increasing the rate of Ca2+ uptake into the SR (2, 3).

However, although all three of these Ca2+ handling pathways contribute to the positive inotropic and lusitropic effects of β-adrenergic stimulation, studies have shown that the PLB/SERCA2a pathway is the dominant pathway responsible for PKA-mediated enhanced cardiac contractility (4, 5). For example, PLB knock out mice (completely devoid of PLB expression) exhibited dramatically enhanced rates of contraction and relaxation, even under basal conditions, and were nearly completely unresponsive to β-adrenergic stimulation of the heart (4). Thus contractility in the
hearts of mice lacking PLB is always near the maximal level, indicating that PKA phosphorylation of PLB is the central pathway responsible for β-adrenergic stimulation of the heart (4).

The effect of PKA phosphorylation of PLB on 45Ca2+-uptake by guinea pig ventricular SR vesicles is shown in Fig. 2 (5). At 50 nM Ca2+ concentration, phosphorylation of PLB by PKA resulted in a two- to four-fold increase in SR Ca2+ up-take relative to control membranes. Fig. 2 also shows the similar stimulatory effect of the anti-PLB monoclonal antibody, 2D12, on SR Ca2+ up-take. 2D12 binds to residues 7-13 of PLB, near the site of PKA phosphorylation (Ser16), and reverses Ca2+ pump inhibition even more potently than PKA phosphorylation of PLB (5, 6). It is important to note that the stimulatory effect of 2D12 on SR Ca2+-uptake was completely inhibited by addition of a PLB peptide (residues 2-25), which binds up the 2D12 antibody. In the same study, the stimulatory effect of 2D12 (and blocking of the stimulatory effect of 2D12 by the PLB peptide 2-25) was also demonstrated in intact cardiomyocytes, confirming that PKA phosphorylation of PLB is the main pathway responsible for β-adrenergic stimulated enhanced contractility (5). It has been suggested by our group that PKA phosphorylation of
PLB and binding of the 2D12 antibody to PLB both reverse Ca\textsuperscript{2+}-pump inhibition by weakening protein-protein interactions between PLB and the Ca\textsuperscript{2+}-ATPase (6).

In response to β-agonist stimulation, PLB is also phosphorylated by CaMKII at Thr\textsuperscript{17}. Like PKA phosphorylation, phosphorylation of PLB by CaMKII reverses PLB inhibition of SERCA2a, and it has been suggested that the effects of dual phosphorylation of PLB (at both Ser\textsuperscript{16} and Thr\textsuperscript{17}) may be additive (2, 3). However, the physiological role of CaMKII phosphorylation of PLB remains unclear (2, 6). Nevertheless, low basal contractility and heart rate are maintained in large part through PLB inhibition of Ca\textsuperscript{2+}-ATPase activity, and cardiac output is increased through β-adrenergic stimulated phosphorylation of PLB by PKA and CaMKII (Fig. 2 and 1-5).

C. THE β-ADRENERGIC PATHWAY AND HEART FAILURE

Although not the direct focus of this dissertation research, it seems important to briefly address the role of PLB in cardiac dysfunction and heart failure. Heart failure is the condition in which the body’s oxygen requirements are not met due to insufficient pumping of blood by the heart. It is a complex and progressive disorder with many causes that develops slowly over time. Heart failure typically results from underlying conditions such as atherosclerosis or hypertension, which either damage the heart muscle directly, or make it harder for the heart to pump blood efficiently (7). In any case, an inefficient cardiovascular system means that the heart must work harder to circulate blood to the body, which leads to pathological growth and remodeling of the heart (7). When left unchecked, this compensatory mechanism often leads to end-stage heart failure and sudden death. On the molecular level, aberrant SR Ca\textsuperscript{2+}-cyling is a characteristic of both cardiac dysfunction and end-stage heart failure (8). Therefore, as a key regulatory complex controlling intracellular Ca\textsuperscript{2+} concentrations and contractility, the role of SERCA2a and PLB in pathological cardiac remodeling and heart failure is currently an active area of investigation (8).

Genetic analysis of individuals with family histories of heart failure led to the discovery of several mutated proteins that cause heritable cardiomyopathies (7). The
preponderance has been found in contractile proteins, including mutations in actin, myosin, and tropomyosin (7). More recently, however, mutated forms of PLB have been identified, which appear to be directly responsible for causing the disease (9-11). In addition, in several recent studies of failing myocardium, reduced SERCA2a expression, altered PLB to SERCA2a ratio, or reduced phosphorylation of PLB was reported (12-14), suggesting that SERCA2a and PLB may be directly involved in the pathogenesis of heart failure. On the contrary, Movsesian et al. reported that SERCA2a and PLB protein levels are unaltered in failing myocardium (15). Regardless, the pivotal role of the PLB/SERCA2a interaction in regulating intracellular Ca^{2+} concentrations and contractility has made them a potential target for therapeutic treatment of heart failure, underscoring the necessity of elucidating the molecular mechanism of PLB action.

D. THE MECHANISM OF Ca^{2+} TRANSPORT BY SERCA2a

SERCA is a large protein of nearly 1000 amino acids that actively transports Ca^{2+} into the lumen of the SR (and counter-transportss luminal H^{+} to the cytoplasm) at the expense of ATP hydrolysis. As a member of the P-type ATPase super-family, SERCA forms a high-energy phosphorylated intermediate as an integral part of its reaction cycle (16). Formation of this high-energy intermediate drives Ca^{2+} transport across the SR membrane, during which the Ca^{2+}-ATPase converts from a high Ca^{2+} affinity state (E1) to a low Ca^{2+} affinity state (E2) (17, 18). Crystal structures of SERCA1a in both the E1 and E2 states have been determined and are shown in cartoon form in Fig. 3B and Fig. 3A, respectively (17, 18). SERCA2a is the cardiac specific isoform of the Ca^{2+} pump, whereas SERCA1a is the isoform found in skeletal muscle (2, 3). The two proteins have high sequence homology with greater than 90% identical amino acid residues (2, 3).

SERCA2a has a large transmembrane domain composed of 10 α-helices (M1-M10), as well as a cytoplasmic head group with three functional domains: nucleotide binding (N) domain, phosphorylation (P) domain, and actuator (A) domain (Fig. 3). ATP binds within the N-domain, and the P-domain contains the conserved Asp^{351} that
is phosphorylated by ATP to form the high-energy acylphosphoprotein intermediate that drives Ca\(^{2+}\) transport across the membrane (17, 18). Specific residues within the A-domain form a TGES loop, which is directly involved in hydrolysis of the phosphorylated intermediate (17, 18). Two Ca\(^{2+}\) binding sites (I and II) are located side by side within the transmembrane domain between transmembrane helices M4, M5, and M6 (17, 18).

A simplified catalytic cycle of SERCA2a, beginning with the high Ca\(^{2+}\) affinity \(E1\cdot ATP\) conformation is shown in Fig. 4. Ca\(^{2+}\) binding at Site I (\(E1\cdot ATP\cdot Ca_1\)) is followed by a slow isomeric transition (\(E1\cdot ATP\cdot Ca_1\) to \(E1'\cdot ATP\cdot Ca_1\)), which facilitates cooperative binding of the second Ca\(^{2+}\) ion at Site II (\(E1\cdot ATP\cdot Ca_2\)). Ca\(^{2+}\) occupancy at both sites triggers transfer of the gamma phosphate of the bound ATP to Asp\(^{351}\) within the P-domain, forming the high-energy

---

Figure 3. Crystal Structures of the \(E2\) and \(E1\) Conformations of SERCA 3-D structures of SERCA1a in the \(E2\) (a) and \(E1\) (b) conformations with bound Thapsigargan and Ca\(^{2+}\) respectively. Image taken directly from Green, N.M and MacLennan (2002) Nature. 418, 598-599 (19).
acylphosphoprotein intermediate, $E_1\sim P\cdot ADP\cdot Ca_2$. Next, as the $Ca^{2+}$ pump converts from $E_1\sim P\cdot ADP\cdot Ca_2$ to $E_2-P\cdot ADP\cdot Ca_2$, $Ca^{2+}$ is transported across the membrane and released into the SR lumen. ADP dissociates (forming $E_2-P$), followed by hydrolytic cleavage of the phosphorylated Asp$^{351}$, producing inorganic phosphate bound, $E_2-P_i$. Dissociation of $P_i$, and subsequent binding of ATP yields $E_2\cdot ATP$. It should be noted that when the enzyme is in the $Ca^{2+}$-free $E_2$ state, the carboxyl groups involved in formation of the $Ca^{2+}$ binding sites are all thought to be protonated, whereas when the enzyme is in the $E_1$ state, the carboxyl groups are not protonated and have a high affinity for $Ca^{2+}$ (18). The high affinity $Ca^{2+}$ pump inhibitor thapsigargin (TG)

**Figure 4. Reaction Cycle of SERCA2a** $E_1$ and $E_2$ represent the high and low $Ca^{2+}$-affinity conformations of SERCA2a, respectively. After sequential binding of two $Ca^{2+}$ ions to $E_1$, the enzyme is phosphorylated with the $\gamma$-phosphate of ATP at Asp$^{351}$, forming the high energy intermediate, $E_1-P$. $Ca^{2+}$ translocation across the SR membrane occurs during the $E_1$ to $E_2$ transition. TG inhibits $Ca^{2+}$-ATPase activity by forming a dead-end complex with the enzyme in $E_2$ ($E_2\cdot TG$) (34). $E_2\cdot TG$ has a greatly reduced affinity for ATP relative to TG-free $E_2$ (61, 62). PLB cross-linking studies indicate that PLB binds preferentially to $E_2$ with bound ATP ($E_2\cdot ATP\cdot PLB$). PLB does not bind to $E_2\cdot TG$ or $E_2$-cyclopiazonic acid (21), $E_2-P$ (22) or to the $Ca^{2+}$ pump with $Ca^{2+}$ binding site 1 (23) or both sites (22, 27) occupied. It is notable that under conditions favoring formation of $E_2$ (the absence of $Ca^{2+}$ and presence of DMSO) the $Ca^{2+}$ pump can be phosphorylated in the reverse direction by $P_i$ forming $E_2\cdot P$. From Akin, B.L., Chen, Z., and Jones, L.R. (2010) *J. Biol. Chem.* **285**, 28540-28552.
inhibits Ca\textsuperscript{2+}-ATPase activity by forming a dead-end complex with the enzyme in E2 (E2·TG), and it was recently suggested that the E2 state stabilized by TG is the fully protonated H\textsubscript{n}E2 state (20 and Fig. 4). Cross-linking studies by our group have suggested that PLB inhibits Ca\textsuperscript{2+} pump turnover by stabilizing the Ca\textsuperscript{2+}-free, E2 state with bound nucleotide, E2·ATP (6, 21-23 and Fig. 4, and as further characterized by this dissertation research).

In addition to its role in catalysis, ATP also interacts with the enzyme in a non-catalytic, modulatory fashion, accelerating multiple steps in the Ca\textsuperscript{2+} pump reaction cycle, including the E2-P to E1·ATP·Ca\textsubscript{2} transition (20). In a recent study by Jensen et al. it was suggested that TG binds to the fully protonated H\textsubscript{n}E2 state of SERCA2a, and that ATP binding at the modulatory site (ATP binding site in E2) accelerates the E2-P to E1·ATP·Ca\textsubscript{2} transition by stimulating deprotonation of E2, initiating the E2 to E1 transition (20). According to the authors, there is a single ATP binding site that converts from modulatory mode (E2·ATP) to catalytic mode (E1·ATP·Ca\textsubscript{2}). In recently published work presented as part of this dissertation research, our group proposed that the conformation of SERCA2a that binds PLB is the deprotonated E2·ATP state with nucleotide bound at the modulatory site (24).

E. PLB STRUCTURE AND FUNCTION

PLB is a 52 amino acid single-span membrane protein localized to the SR of cardiac and smooth muscle cells (2, 3). Monomeric PLB has two structural domains: a cytosolic N-terminal domain I (residues 1-32), and a C-terminal transmembrane
domain II (residues 33-52) (Fig. 5). Early analysis of PLB by SDS-PAGE showed that PLB monomers oligomerize to form stable homo-pentamers (2, 3). Subsequent mutational analysis showed that the PLB pentamer is stabilized by an intra-molecular Leu/Ile zipper, formed by residues leu$^{37}$, leu$^{44}$, leu$^{51}$, Ile$^{40}$, and Ile$^{47}$ within transmembrane domain II (25), and mutation of any of the residues to Ala destabilizes PLB pentamer formation and enhances Ca$^{2+}$ pump inhibition by PLB (26, 27). Based upon these results it was concluded the PLB monomer is the active species that binds to and inhibits Ca$^{2+}$ pump activity, and that PLB inhibitory function is increased by mutations that increase PLB monomer content in the membrane (26, 27). Due to their ability to decrease the Ca$^{2+}$ affinity of SERCA2a (increase the $K_{Ca}$ of enzyme activation) more than wild-type PLB, these superinhibitory monomeric PLB mutants were termed “supershifters” (26). Subsequent mutagenesis studies showed that Ca$^{2+}$ pump inhibition by PLB was also enhanced by mutations that did not affect the PLB monomer to pentamer ratio observed by SDS-PAGE (22, 28). It was proposed that these superinhibitory PLB mutants retaining the ability to form pentamers must have an increased binding affinity for the Ca$^{2+}$ pump relative to wild-type PLB (22, 28). Collectively, all of these results suggested that there is dynamic equilibrium between PLB pentamers, PLB monomers, and PLB/SERCA2a heterodimers in the membrane, and PLB inhibition of Ca$^{2+}$-ATPase activity is enhanced by point mutations that either increase PLB monomer formation by destabilizing the PLB pentamer (e.g. L37A (26, 27)), or otherwise enhance PLB monomer binding interactions with the Ca$^{2+}$ pump (e.g. N27A (28) and V49G (22)).

Consistent with these in vitro studies, depressed cardiac function and super-inhibition of the Ca$^{2+}$-ATPase was observed transgenic mice overexpressing monomeric PLB supershifters (L37A (29)) and PLB supershifters retaining the ability to form pentamers (N27A (30) and V49G (31)), relative to mice overexpressing wild-type PLB. Mice overexpressing the pentameric PLB supershifters developed cardiac hypertrophy, dilated cardiomyopathy and premature death compared to mice overexpressing wild-type PLB (30, 31). Moreover, whereas isoproterenol stimulation (activating the $\beta_1$-adrennergic pathway) completely reversed Ca$^{2+}$-ATPase inhibition by the monomeric PLB supershifters, isoproterenol stimulation was not sufficient to
completely reverse the inhibitory effects of the more potent pentameric PLB supershifters (30-31). These findings are consistent with the theory that PLB supershifters retaining the ability to form pentamers have a higher binding affinity for the Ca\(^{2+}\) pump relative to wild-type PLB.

**F. DEVELOPING A MODEL OF PLB REGULATION OF SERCA2a USING CHEMICAL CROSS-LINKING**

The work discussed thus far clearly demonstrates that PLB is a key regulator of myocardial contractile kinetics, and that proper regulation of Ca\(^{2+}\)-ATPase activity by PLB is required for normal cardiac function and survival. Yet despite its prominent role in regulating cardiac function, the physical basis of enzyme inhibition by PLB has remained unclear, and presently several fundamentally different models exist.

A major impediment to solving the molecular mechanism of PLB regulation of SERCA2a has been an inability to measure PLB binding interactions with the Ca\(^{2+}\) pump. Our group has overcome this hurdle using chemical cross-linking. PLB can be irreversibly covalently coupled to SERCA2a in native membranes, facilitating direct measurement of PLB binding to SERCA2a. This technique has enabled us to study protein-protein interactions

---

**Figure 6. Structural Model for the Interaction Between PLB and SERCA2a**

A, Two independent structures for PLB were docked next to the structure of the E2 state of SERCA bound to TG. The cyan PLB was derived from a monomeric mutant, whereas the yellow PLB was extracted from the pentameric structure of a construct corresponding to the WT human sequence. B, Close-up of the C-terminus of PLB. It is wedged between the lumenal end of M2 and a loop between M9 and M10 of SERCA (colored blue), suggesting that M2 must move to accommodate PLB binding and that Val\(^{49}\) controls access to this binding site. Taken directly from Chen, Z., Akin, B.L., Stokes, D.L., and Jones, L.R. (2006) *J.Biol.Chem.* **281**, 14163-14172.
between PLB and SERCA2a, and the allosteric factors that controlling the interaction (6, 21-24). Using chemical cross-linking we have identified several key points of interaction between PLB and the Ca$^{2+}$ pump, which in conjunction with the crystal structures of the enzyme (17, 18) enabled us to model the three-dimensional interactions between the two proteins (Fig. 6).

In initial cross-linking studies, fully functional, Cys-less PLB (with Cys residues 36, 41, and 46 mutated to Ala) was used as a background for making Cys scanning point mutants of PLB. Lone Cys residues inserted at discrete locations within PLB were then probed for cross-linking to Cys or Lys residues of SERCA2a using homo (thiol specific), or heterobifunctional (thiol to amine specific) cross-linking reagents, respectively. Cys residues within both domain I (cytoplasmic) and domain II (transmembrane) of PLB have been cross-linked to Cys and Lys residues of SERCA2a at the cytoplasmic extension of M4 and at the C-terminus of M2 (Fig. 7).

Figure 7. Sites of PLB Cross-linking to SERCA2a with Homo- and Hetero-bifunctional Cross-linkers PLB mutants have been cross-linked to SERCA2a cytoplasmic extension of M4 (red) and at the C-terminus of M2 (green). Modified from Jones, L.R., Cornea, R.L., and Chen, Z. (2002) J. Biol. Chem. 277, 28319-28329.
PLB cross-linking to SERCA2a at each of these sites was completely inhibited by micromolar Ca$^{2+}$ concentration (Fig. 8). This suggests that binding of PLB and Ca$^{2+}$ to SERCA2a is mutually exclusive. Importantly, when Ca$^{2+}$ inhibition of PLB cross-linking was correlated with Ca$^{2+}$ stimulation of Ca$^{2+}$-ATPase activity, cross-linking was inhibited over the same range of Ca$^{2+}$ concentration as Ca$^{2+}$-ATPase activity was stimulated. This is exemplified in Fig. 9, which shows the cross-linking curve of N30C-PLB to Cys$^{318}$ of WT-SERCA2a, correlated with the ATPase activity measured from the same microsomal prep. Note that as micromolar Ca$^{2+}$ increases, PLB cross-linking to SERCA2a is inhibited (panel A), whereas the Ca$^{2+}$-ATPase is activated (panel B). An inverse relationship between PLB cross-linking to SERCA2a and Ca$^{2+}$ pump inhibition has proven consistent with all cross-
linking pairs discovered to date, strongly suggesting that PLB competes with Ca$^{2+}$ for binding to the enzyme. Consistent with this interpretation, assays measuring Ca$^{2+}$ inhibition of PLB cross-linking indicate that when PLB is phosphorylated by PKA, a lower concentration of Ca$^{2+}$ is required to dissociate PLB from Ca$^{2+}$ pump (Fig. 10). This suggests that phosphorylation of PLB at Ser$^{16}$ by PKA decreases its binding affinity for the Ca$^{2+}$ pump.

Figure 9. Effect of Ca$^{2+}$ on Cross-linking of N30C-PLB to SERCA2a with BMH A, Ca$^{2+}$ inhibition of PLB N30C-PLB cross-linking with BMH. B, Ca$^{2+}$-ATPase activity of the same microsomal preparation measured in the presence and absence of the anti-PLB antibody, 2D12, which reverses PLB inhibition like phosphorylation by protein kinase A. Taken from Jones, L.R., Cornea, R.L., and Chen, Z. (2002) J. Biol. Chem. 277, 28319-28329.

Figure 10. Ca$^{2+}$ Effect on Cross-linking of Phosphorylated and Dephosphorylated PLB to SERCA2a PLB pre-phosphorylated in the presence (PKA) or absence (Con) of PKA was cross-linked to SERCA2a at varying Ca$^{2+}$ concentrations. The inset shows the immunoblot with anti-PLB antibody obtained after cross-linking. Plot depicts cross-linking inhibition as a function of ionized Ca$^{2+}$ concentration. Taken directly Chen, Z., Akin, B.L., and Jones, L.R. (2007) J. Biol. Chem. 282, 20968-20976.
In addition to being completely inhibited by micromolar Ca\(^{2+}\) concentration (Figs. 8-10), another hallmark of the PLB to SERCA2a cross-linking reaction is its nucleotide dependence. ATP stimulated PLB cross-linking to SERCA2a by 2-3-fold at nearly all cross-linking sites tested when measured in the absence of Ca\(^{2+}\) (Fig. 11). This suggests that PLB binds preferentially to nucleotide-bound E2 state (E2·ATP). PLB cross-linking to SERCA2a was also stimulated by ADP, but was unaffected by AMP, measured in the absence of Ca\(^{2+}\) (21). This indicates that the β-phosphate of the nucleotide is involved in formation of the E2 state that binds PLB.

Early kinetic studies showed that the E2 state of SERCA2a could be phosphorylated in the reverse direction by P\(_i\) to form E2-P (E2 + P\(_i\) → E2-P, or “back-door phosphorylation”) (32, 33). It was also shown that there are two distinct E2 conformations of SERCA2a: one with bound ATP (E2·ATP) which cannot be phosphorylated by P\(_i\), and a second stabilized by low pH or Me\(_2\)SO that is readily phosphorylated by P\(_i\) to form E2-P\(_i\) (32, 33). When PLB cross-linking to SERCA2a was measured simultaneously with E2-P formation by P\(_i\), ATP stimulated PLB cross-linking to SERCA2a over the same concentration range as ATP inhibited formation of E2-P (Fig. 12). Based upon these results it was concluded that PLB binds to E2·ATP, but not to E2-P or E2·P\(_i\) (22).
A final signature characteristic of the PLB to SERCA2a cross-linking reaction is its sensitivity to the Ca\textsuperscript{2+} pump inhibitor TG. TG binds with nanomolar affinity to the Ca\textsuperscript{2+}-ATPase in \textit{E2}, forming a dead-end complex, \textit{E2-TG}, and irreversibly inhibiting the enzyme (34, 35 and Fig. 2). Measured in the absence of Ca\textsuperscript{2+}, TG

---

**Figure 12. ATP Concentration-Dependence on Cross-linking and \textit{E2-P} Formation** N30C-PLB co-expressed with WT-SERCA2a (A) and V49C-PLB co-expressed with V89C-SERCA2a (B) was cross-linked in \textit{E2-P} buffer. Upper autoradiograms show \textit{E2-P} formation, and middle autoradiograms show PLB cross-linked to SERCA2a. The bottom graph shows the ATP concentration-dependence for stimulation of PLB-cross-linking to SERCA2a (open symbols) and for inhibition of \textit{E2-P} formation (filled symbols). In the plot, baseline values obtained in the absence of ATP were set at 0% and 100% for protein cross-linking and \textit{E2-P} formation, respectively (n = 5). Taken directly from Chen, Z., Akin, B.L., Stokes, D.L., and Jones, L.R. (2006) \textit{J.Biol.Chem.} \textbf{281}, 14163-14172.
completely inhibits PLB cross-linking to SERCA2a (Fig. 13A and B). This indicates that PLB does not bind to the E2 state of SERCA2a stabilized by TG. When ATP was included in assays measuring TG effects on PLB cross-linking, the \( K_i \) for TG inhibition of PLB cross-linking was increased by approximately 4-fold (Fig. 13C), strongly supporting the idea that PLB binds preferentially with the nucleotide bound Ca\(^{2+}\)-ATPase in E2.

![Figure 13. TG Inhibition of Cross-Linking of Residues 45-52 of PLB to V89C-SERCA2a](image)


Collectively, these cross-linking results point to a simple mechanism of PLB regulation of SERCA2a shown in **Fig. 14**. PLB stabilizes a single unique conformation of the Ca\(^{2+}\) pump, the low Ca\(^{2+}\) affinity \( E2 \cdot \text{ATP} \) state and blocks the transition to \( E1 \), the conformation required for high-affinity Ca\(^{2+}\) binding and ATP hydrolysis. SERCA2a with PLB bound cannot bind Ca\(^{2+}\) and is catalytically inactive, and PLB must completely dissociate before the enzyme can transition to \( E1 \) and initiate Ca\(^{2+}\) transport. By antagonizing formation of \( E1 \), PLB significantly decreases the fraction of Ca\(^{2+}\) pumps available to transport Ca\(^{2+}\) at sub-saturating Ca\(^{2+}\)
concentration. This is manifested as a decrease in the apparent Ca\textsuperscript{2+} affinity of the Ca\textsuperscript{2+}-ATPase, the hallmark of PLB inhibition (2, 3). At saturating Ca\textsuperscript{2+} concentration PLB is not bound to the enzyme, therefore, PLB has no effect on maximal Ca\textsuperscript{2+}-ATPase activity. Phosphorylation of PLB by PKA and binding of the 2D12 antibody to PLB decrease the affinity of SERCA2a for PLB, allowing PLB inhibition of Ca\textsuperscript{2+}-ATPase activity to be reversed at a lower Ca\textsuperscript{2+} concentration.

![Diagram of PLB regulation of SERCA2a activity]

**Figure 14. Our Model of PLB Regulation of SERCA2a Activity** There is a dynamic equilibrium between PLB pentamers, PLB monomers, and PLB/SERCA2a heterodimers. PLB binds exclusively to the $E_2\cdot$ATP conformation of the Ca\textsuperscript{2+} pump and immobilizes it in this state. Ca\textsuperscript{2+}-ATPase inhibition by PLB is reversed by complete dissociation of PLB from SERCA2a, induced by micromolar Ca\textsuperscript{2+} concentration or by PLB phosphorylation and low micromolar Ca\textsuperscript{2+} concentration.
This model of mutually exclusive binding of PLB and Ca\(^{2+}\) is consistent with the crystal structures of SERCA2a determined in both the \(E1\) and \(E2\) states (17, 18). Cross-linking studies predict that PLB binds to \(E2\) of SERCA2a within a groove formed between transmembrane helices M2, M4, and M9 (Fig. 6). When SERCA2a is in \(E1\) with bound Ca\(^{2+}\), this groove is closed at the C-terminus (17, 18), blocking PLB access to the binding pocket.

However, despite strong biochemical and structural evidence supporting this model of PLB regulation of SERCA2a, several alternate models of PLB inhibition have recently emerged. These models differ from the model just described in three main respects:

1) We maintain that PLB binding interactions with SERCA2a are dynamic, and PLB associates and dissociates from the enzyme in a Ca\(^{2+}\)-dependent fashion. On the other hand, other groups maintain that PLB is essentially a subunit of SERCA2a that remains tightly bound to the enzyme throughout the catalytic cycle (36, 37).

2) According to our model, PLB binds exclusively to the \(E2\cdot\text{ATP}\) conformation of the Ca\(^{2+}\) pump and blocks the \(E2\) to \(E1\) transition. However, others have suggested that PLB acts elsewhere, or at multiple points in the catalytic cycle to slow or inhibit enzyme turnover (36-41).

3) Our model states that high Ca\(^{2+}\) concentration completely dissociates PLB from the Ca\(^{2+}\) pump. Therefore, at saturating Ca\(^{2+}\) concentration, PLB is not bound, and has no effect on maximal Ca\(^{2+}\)-ATPase activity. On the contrary, several recent studies have reported that PLB either decreased or increased the \(V_{\text{max}}\) of the Ca\(^{2+}\)-ATPase at saturating Ca\(^{2+}\) concentration (42-45).

G. PURPOSE

The purpose of this dissertation research was to critically evaluate our model of PLB regulation of SERCA2a, and to clarify the major points of discrepancy
between our model and the other current models. To do this I proposed three hypotheses to be tested, each one specifically designed to address a fundamental point in the mechanism of PLB action.

1. HYPOTHESIS 1: SERCA2a WITH PLB BOUND IS CATALYTICALLY INACTIVE

There are two schools of thought with respect to PLB binding interactions with SERCA2a. In the first, PLB is essentially a subunit of SERCA2a that remains tightly bound to the enzyme throughout its entire reaction cycle. Using fluorescent probes to monitor interactions between PLB and SERCA in both reconstituted and native membranes, Li et al. (36) and Chen et al. (37) concluded that PLB binds so tightly to SERCA2a that it essentially never dissociates, remaining bound to the enzyme throughout the full catalytic cycle. On the other hand, several groups, including ours, have shown that there is a dynamic equilibrium between PLB pentamers, PLB monomers, and PLB-SERCA heterodimers (21, 46-50). Moreover, based upon our recent work with chemical cross-linking we have proposed that PLB stabilizes the Ca\(^{2+}\) free, \(E_2\cdot ATP\) conformation of SERCA2a and blocks the \(E_2\) to \(E_1\) transition. In order for enzyme to transition to \(E_1\) and initiate Ca\(^{2+}\) transport, PLB must first completely dissociate from the enzyme (6, 21-23). Thus, at any given time within a cardiomyocyte, there are two distinct populations of SERCA2a: one inactive population of SERCA2a with bound PLB (SERCA2a\(\cdot\)PLB), and a second active, PLB-free population, pumping Ca\(^{2+}\) at the normal rate.

a. TESTING THE CATATLYTIC ACTIVITY OF SERCA2a WITH PLB BOUND

To address this point of uncertainty, I developed a method to test the catalytic activity of SERCA2a with PLB irreversibly bound to it. First, chemical cross-linkers were used to covalently couple PLB to SERCA2a to form PLB/SER (PLB/SER refers to PLB covalently cross-linked to SERCA2a), and Ca\(^{2+}\)-ATPase activity was
measured. Then, [γ-32P]ATP and 32P_i were used to phosphorylate PLB/SER, in order to determine if SERCA2a can undergo the catalytic half-reactions to form E1–P and E2–P, respectively, when PLB is bound. Finally, PLB-free SERCA2a was resolved from PLB/SER via a cross-linking induced mobility-shift on LDS-PAGE, while maintaining the labile acyl-phosphate of E1–P and E2–P. These experiments revealed that PLB/SER was entirely catalytically inactive and unphosphorylatable by either [γ-32P]ATP or 32P_i, and thus forcibly kinetically stalled by the binding of PLB.

2. HYPOTHESIS 2: PLB DECREASES THE Ca^{2+} AFFINITY OF SERCA2a BY COMPETING WITH Ca^{2+} FOR BINDING TO SERCA2a

It is generally accepted that PLB decreases the apparent Ca^{2+} affinity of the SERCA2a, while having little or no effect on the V_{max} of the enzyme measured at saturating Ca^{2+} concentration (2, 3). However, whether PLB increases the K_{Ca} of Ca^{2+}-ATPase activation by decreasing the actual Ca^{2+} binding affinity of the enzyme (21, 23, 44, 51) or by affecting one or more catalytic steps in the reaction cycle (36-41) has remained unclear. Cantilina et al. (38) originally proposed that that PLB decreases the apparent Ca^{2+} affinity of SERCA2a by slowing the isomeric transition that follows binding of the first Ca^{2+} ion, enabling cooperative binding of the second Ca^{2+} ion. According to this model, PLB does not affect the actual Ca^{2+} binding affinity of SERCA2a (the actual amount of Ca^{2+} bound to the enzyme at a given low Ca^{2+} concentration), but rather the kinetics of enzyme activation by bound Ca^{2+}. On the other hand, our cross-linking results suggest that mutually exclusive binding of PLB and Ca^{2+} is the underlying mechanism of Ca^{2+}-ATPase inhibition by PLB. If PLB competes for Ca^{2+} binding to SERCA2a by stabilizing the Ca^{2+}-free enzyme in E2, and antagonizing formation of E1, then by mass action, PLB should decrease the fraction of Ca^{2+} pumps available to bind and transport Ca^{2+} at sub-saturating Ca^{2+} concentration. This would be manifested as a decrease in the apparent Ca^{2+} affinity of the Ca^{2+}-ATPase (2, 3).
a. USING CROSS-LINKABLE PLB SUPERSHIFTERS TO TEST FOR COMPETITIVE BINDING OF PLB AND Ca\(^{2+}\) TO SERCA2a

Ideally, to test the theory that PLB competes with Ca\(^{2+}\) for binding to SERCA2a, Ca\(^{2+}\) binding assays would be used to directly determine if a population of Ca\(^{2+}\) pumps expressed alone and free from PLB bind Ca\(^{2+}\) with higher affinity than a population of Ca\(^{2+}\) pumps co-expressed with PLB. Unfortunately, accurate measurement of Ca\(^{2+}\) binding affinity with \(^{45}\)Ca\(^{2+}\) requires relatively high expression levels of the Ca\(^{2+}\) ATPase (52), which is difficult to achieve in recombinant systems (53). As an alternative, we have shown that the Ca\(^{2+}\) affinity of the enzyme is accurately estimated by assaying Ca\(^{2+}\) inhibition of PLB cross-linking to SERCA2a. For example, Fig. 9 shows that PLB cross-linking was inhibited by micromolar Ca\(^{2+}\) concentration over the same concentration range as enzyme activation occurs. However, since cross-linking assays cannot be used to assess the Ca\(^{2+}\) affinity of SERCA2a expressed alone, the direct effect of PLB on Ca\(^{2+}\) affinity has yet to be determined. I overcame this limitation by instead comparing the effects of series of cross-linkable PLB mutants of increasing inhibitory strength on Ca\(^{2+}\) binding to the Ca\(^{2+}\) pump. If PLB competes for Ca\(^{2+}\) binding to the Ca\(^{2+}\)-ATPase, then as PLB becomes a stronger inhibitor of enzyme activity, higher concentrations of Ca\(^{2+}\) should be required to dissociate it from the Ca\(^{2+}\) pump.

Two cross-linkable supershifters, PLB3 (N27A, N30C, L37A-PLB) and PLB4 (N27A, N30C, L37A, V49G-PLB), were made by combining the N30C cross-linking mutation with other gain-of-function mutations (Fig. 15). PLB3 and PLB4 are strongly inhibitory compared to N30C-PLB (which has a normal inhibitory strength (21)), while remaining cross-linkable to the Ca\(^{2+}\)-pump, thus allowing their physical interactions with SERCA2a to be measured simultaneously with their functional effects on enzyme activity. The results, described in detail below, showed that higher concentrations of Ca\(^{2+}\) were required to both activate the enzyme co-expressed with the increasingly inhibitory PLB mutants and to dissociate the PLB mutants from the Ca\(^{2+}\) pump, consistent with PLB competing with Ca\(^{2+}\) for binding to the enzyme.
b. USING CROSS-LINKABLE PLB SUPERSHIFTERS IN CONJUNCTION WITH D351A-SERCA2a TO TEST FOR COMPETITIVE BINDING OF PLB AND Ca²⁺

To test directly for competition between PLB and Ca²⁺ for binding to SERCA2a, I also took advantage of the Ca²⁺-pump mutant, D351A. During catalysis, Asp³⁵¹ is phosphorylated by ATP to form the high-energy acylphosphoprotein intermediate, $E_1\cdot P\cdot Ca_2^+$ (Fig. 4). Replacement of aspartic acid at this position renders the enzyme catalytically inactive (53, 54). Although inactive at the site of ATP hydrolysis, D351A retains the ability to bind Ca²⁺ and maintains the thermodynamic
equilibrium between $E_1$ and $E_2$ (53, 55, 56). Therefore, if PLB acts by stabilizing $E_2$ and shifting the $E_1 \cdot \text{Ca}_2 \leftrightarrow E_2 \cdot \text{PLB}$ equilibrium away from $E_1$, then like the wild-type enzyme, higher concentrations of Ca$^{2+}$ should be required to dissociate the increasingly inhibitory PLB mutants from D351A. The advantage of using D351A for these experiments is that enzyme turnover is prevented, therefore the system is at equilibrium with respect to Ca$^{2+}$ binding (Fig. 4). The results showed that like wild-type SERCA2a, higher concentrations of Ca$^{2+}$ were required to inhibit cross-linking of the increasingly inhibitory PLB mutants to D351A.

c. DETERMINING THE EFFECT OF PLB ON MAXIMAL CA$^{2+}$-ATPASE ACTIVITY

If PLB binding and Ca$^{2+}$ binding to SERCA2a are mutually exclusive, and micromolar Ca$^{2+}$ concentration completely dissociates PLB from the Ca$^{2+}$ pump, then at saturating Ca$^{2+}$ concentration PLB should have no effect on maximal enzyme activity, relative to SERCA2a expressed alone. On the other hand, in several recent studies PLB was reported to either decrease (44) or increase (42, 43, 45) the $V_{\text{max}}$ of the Ca$^{2+}$-ATPase. To address this discrepancy directly, maximal Ca$^{2+}$-ATPase activity of SERCA2a expressed alone was compared to that of SERCA2a co-expressed with PLB mutants of normal (N30C-PLB) and superinhibitory strength (PLB3 and PLB4). Importantly, prior to functional analysis, quantitative Western blotting was used to carefully determine protein expression levels in the membranes, and Ca$^{2+}$-ATPase activities were corrected for variability in SERCA2a expression between preparations. The results showed that PLB molecules of normal inhibitory strength (N30C-PLB) did not significantly affect the $V_{\text{max}}$ of the Ca$^{2+}$-ATPase, whereas the superinhibitory PLB mutants, PLB3 and PLB4, reduced the $V_{\text{max}}$ of the enzyme substantially.
3. HYPOTHESIS 3: PLB BINDS EXCLUSIVELY TO THE E2·ATP

CONFORMATION OF THE Ca²⁺ PUMP

a. INVESTIGATING THE CONFORMATIONAL SPECIFICITY

OF THE PLB TO SERCA2a BINDING INTERACTION USING

THE EFFECTORS TG, VANADATE, AND NUCLEOTIDES

(ATP, ADP AND AMP)

In previous studies we have shown that PLB cross-linking to SERCA2a is completely inhibited by Ca²⁺ (E1·Ca₂), thapsigargin (E2·TG), and P₁ (E2·P₁ and E2-P), but augmented substantially by ATP (6, 21-23). Based upon these results we proposed that PLB binds exclusively to the Ca²⁺-free E2 state of SERCA2a, preferentially with bound nucleotide, E2·ATP. According to this model, the superinhibitory PLB mutants, PLB3 and PLB4, should also bind preferentially to the E2·ATP state, only more tightly than N30C-PLB. Therefore, to gain further insights on the specific conformation of the Ca²⁺ pump that binds PLB, and to estimate the relative binding affinities of the PLB mutants for SERCA2a, the effects of thapsigargin, vanadate, and nucleotides on PLB cross-linking to SERCA2a were determined. The results indicate that the PLB supershifters also act by stabilizing the E2·ATP conformation of the Ca²⁺ pump. Moreover, we were able to estimate the binding affinity of the different PLB mutants for SERCA2a. In the presence of ATP, N30C-PLB had an affinity for E2·ATP approaching that of vanadate (micromolar), whereas PLB3 and PLB4 had much higher affinities, several fold greater than even TG, the highest affinity SERCA2a inhibitor yet reported (nanomolar or higher).
CHAPTER 2—EXPERIMENTAL PROCEDURES

A. MATERIALS

The cross-linking agent KMUS was purchased from Pierce. [γ-32P]ATP was obtained from PerkinElmer Life Sciences, and thapsigargin and sodium orthovanadate were purchased from Sigma.

B. MUTAGENESIS AND BACULOVIRUS PRODUCTION

The baculovirus expression system was used to co-express the canine isoforms of both WT and mutant SERCA2a and PLB in insect cell membranes. Mutation of canine SERCA2a and PLB cDNAs was conducted as described previously (27). For consistency with previous cross-linking studies, N30C-PLB was made on the Cys-less PLB background, in which Cys residues 36, 41, and 46 were mutated to Ala (21). N30C-PLB has been previously well characterized, and is fully functional with an inhibitory potency similar to wild-type PLB (21). In control experiments, identical results were obtained when N30C-PLB was made on the wild-type PLB background with Cys residues 36, 41, and 46 unaltered (data not shown). cDNAs encoding PLB3 and PLB4 were generated on the wild-type PLB cDNA background inserted in the transfection vector pVL1393, using the QuickChange™ XL-Gold system (Stratagene). D351A was made similarly using canine cardiac SERCA2a cDNA as the template (21). All mutated cDNAs were confirmed by DNA sequencing of the plasmid vectors. Baculoviruses encoding mutated proteins were generated as described previously with BaculoGold™ (Pharmengen) linearized baculovirus DNA (21).

C. PROTEIN EXPRESSION AND CHARACTERIZATION

Sf21 insect cells were co-infected with baculoviruses encoding PLB and SERCA2a as described previously (27). Viral titers were adjusted to give an expression level of PLB to SERCA2a of approximately 4:1, as used in previous publications (6, 21-23). Cells were harvested 60 h after co-infection, washed with
phosphate-buffered saline, and homogenized with a Polytron for 90 s at 15,000 rpm. Crude microsomal pellets were then collected by centrifuging at 48,000 x g for 20 min. Microsomes were re-suspended at a protein concentration of 6-10 mg/ml in 0.25 M sucrose, 10 mM MOPS (pH 7.0) and stored frozen in small aliquots at -40 °C. Protein concentrations were determined by the Lowry method. PLB and SERCA2a contents in the membrane samples were determined by quantitative Western blotting with the monoclonal antibodies, 2D12 and 2A7-A1, respectively (21). Only membranes expressing PLB and SERCA2a at a molar ratio of approximately 4:1 were used for further analyses.

D. Ca\(^{2+}\)-ATPASE ASSAY

Ca\(^{2+}\)-ATPase activities were measured at 37 °C in buffer containing 50 mM MOPS (pH 7.0), 100 mM KCl, 3 mM MgCl\(_2\), 3.0 mM ATP, 5 mM NaN\(_3\), 3 µg/ml of the Ca\(^{2+}\) ionophore, A23187, and 1 mM EGTA. Ionized Ca\(^{2+}\) concentrations were set by varying the CaCl\(_2\) concentration from 0-1.2 mM. In certain assays, only maximal Ca\(^{2+}\)-ATPase activity was measured in the absence of EGTA and with 50 µM added CaCl\(_2\) (Figs. 16 and 17). Some assays were conducted in the presence and absence of the anti-PLB monoclonal antibody, 2D12, which reverses PLB inhibition of SERCA2a (5, 6, 57). Ca\(^{2+}\)-dependent ATPase activities were determined in a reaction volume of 1 ml containing 50 -100 µg of membrane protein during a 30 - 60 min incubation. P\(_i\) release from ATP was measured colorimetrically (21). Maximal Ca\(^{2+}\)-ATPase activities ranged between 15 and 25 µmol of P\(_i\)/mg of protein/h for all samples, which is approximately 25-40% of the maximal Ca\(^{2+}\)-ATPase activity typically reported for dog cardiac SR vesicles (57). In some Ca\(^{2+}\)-ATPase assays, small aliquots were taken from the assay tubes during the incubations, in order to simultaneously measure PLB cross-linking to SERCA2a (see below). K\(_{Ca}\) values are the Ca\(^{2+}\) concentrations at which the Ca\(^{2+}\)-ATPase is half maximally active as determined directly from the data plots.
E. CROSS-LINKING PLB TO SERCA2a

1. STANDARD CROSS-LINKING (SMALL SCALE)

In most experiments, cross-linking of N30C of PLB to Lys$^{328}$ of SERCA2a with KMUS was conducted identically as previously described (22). Cross-linking reactions were conducted with 11 µg of membrane protein in 12 µl of buffer. The final concentrations of PLB and SERCA2a in the cross-linking tubes were 1.2 µM and 0.3 µM, respectively. Standard cross-linking buffer contained 50 mM MOPS (pH 7.0), 3.0 mM MgCl$_2$, 100 mM KCl, 3 mM ATP, and 1 mM EGTA with zero to 1.2 mM added CaCl$_2$. In some experiments, ATP concentrations were varied, or different nucleotides were used, as indicated in the figure legends. In the experiments with the SERCA2a inhibitors TG and vanadate, TG was added from a 1 mM stock solution in ethanol, and sodium orthovanadate was added from a 15 mM stock solution in H$_2$O. Cross-linking reactions were started by adding 0.75 µl of 1.6 mM KMUS dissolved in Me$_2$SO (final KMUS concentrations 0.1 mM), and incubated for 2 min at room temperature. Reactions were stopped by adding 7.5 µl of gel loading buffer containing 15% SDS and 100 mM dithiothreitol. Samples were subjected to SDS-PAGE, and Western blotting with the anti-PLB antibody, 2D12, using $^{125}$I-protein A or alkaline phosphatase for PLB visualization. In the experiments measuring the effects of 2D12, blots were probed directly with $^{125}$I-2D12, and protein A was omitted (6). Radioactive signals (representing SERCA2a with bound PLB) were quantified using a Bio-Rad Personal Fx Phosphoimager. The $K_i$ values for inhibition of PLB cross-linking were determined directly from the data plots, and is the Ca$^{2+}$, TG, or vanadate concentration at which cross-linking was 50% inhibited.

2. LARGE SCALE CROSS-LINKING

In order test the catalytic activity of PLB-bound SERCA2a, PLB was cross-linked to SERCA2a on large-scale (PLB/SER), and then the catalytic activity of PLB/SER was determined by measuring its ability to hydrolyze ATP and to be phosphorylated with $[\gamma^{32}P]$ATP or $^{32}$P, to form $E1$-$P$ and $E2$-$P$, respectively. “Pre-cross-linking” the membranes on large scale in advance allowed for multiple
phosphorylation experiments (by both $[^\gamma^32P]ATP$ and $^{32}P_i$) to be performed on identical membranes, eliminating a potential source of variability. Also, pelleting and re-suspending the cross-linked membranes prior to storage eliminated the excess cross-linker, ATP, and Ca$^{2+}$ present during the initial cross-linking reaction.

Large scale cross-linking was done similar to the standard cross-linking described above, only 2.75 mg instead of 11 µg of membranes were used per reaction tube, and 300 µl Ca$^{2+}$-EGTA buffer was added to achieve free Ca$^{2+}$ concentrations between 0 and 16.7 µM. Reactions were started with the addition of 187 µl of 1.6 mM KMUS in Me$_2$SO and incubated for 3 min; the final reaction volume was 3 ml. The reactions were stopped with the addition of 125 µl of 500 mM glycine and 500 mM DTT. The cross-linked membranes were centrifuged for 10 min at 100 K at 4 °C in a Beckman TL-100 centrifuge. The membranes were re-suspended in 10 mM MOPS and 0.25 M sucrose (pH 7.2) and stored in small aliquots at -80 °C.

3. CROSS-LINKING UNDER Ca$^{2+}$-ATPASE CONDITIONS

To assess Ca$^{2+}$ effects on PLB cross-linking to SERCA2a, experiments were conducted at 37 °C in the same buffer used for measurement of Ca$^{2+}$-ATPase activity, as described above. 15 min after initiation of Ca$^{2+}$-ATPase reactions with ATP, 80 µl aliquots containing 8 µg of membrane protein were taken from Ca$^{2+}$-ATPase assay tubes and cross-linked with 1 mM KMUS for 15 s, giving the maximal cross-linking obtainable at each Ca$^{2+}$ concentration tested. Reactions were stopped with gel loading buffer, and samples were then processed as described above. Cross-linking of PLB to D351A to assess Ca$^{2+}$ affinity was determined under identical conditions.

It should be pointed out that the heterobifunctional cross-linker KMUS reacts irreversibly with Lys$^{328}$ of SERCA2a and N30C of PLB whether the two proteins are bound or not. If the two proteins are bound when the cross-linker is added, then PLB is irreversibly cross-linked to SERCA2a by a single KMUS molecule. If the proteins are not bound when the cross-linker is added, then N30C of PLB can react with one KMUS molecule, and Lys$^{328}$ of SERCA2a can react with a second KMUS molecule, thus blocking additional cross-linking of the two proteins as new PLB-SERCA2a
complexes are formed. Therefore, the amount of PLB-SERCA2a complex detected by cross-linking is essentially a "snapshot" of the amount of PLB-SERCA2a complex present at the time at which the cross-linker is added.

F. MONITORING FORMATION OF THE PHOSPHORYLATED INTERMEDIATES, E1-P AND E2-P

1. PHOSPHORYLATION OF E1-Ca₂⁡ by [γ-³²P]ATP

Phosphorylation of SERCA2a using [γ³²P]ATP was conducted by incubating 11 μg of membrane protein (virgin membranes or pre-cross-linked membranes) in 12 μl buffer containing 50 mM MOPS (pH 7.0), 3.0 mM MgCl₂, 100 mM KCl, 1 mM EGTA, and 0 to 1.2 mM CaCl₂. Maximal E1-P formation was measured in the absence of EGTA and with 1 mM added CaCl₂. Phosphorylation was initiated by adding a final concentration of 200 μM [γ³²P]ATP and conducted for 5 s at room temperature. Reactions were terminated with 7.5 μl of acidic gel loading buffer (pH 2.4) containing 3% LDS, and LDS-PAGE was conducted under acidic conditions as recently described (22). After electrophoresis, proteins were transferred to nitrocellulose and the radioactive acylphosphoprotein bands were visualized by autoradiography and quantified with the Fx Phosphoimager.

2. PHOSPHORYLATION OF E2 By ³²P₁ (BACK DOOR PHOSPHORYLATION)

Phosphorylation of SERCA2a by ³²P₁ to form E2-P was done in buffer favoring formation of E2 (i.e. at pH 7.0, in the presence Me₂SO and in the absence of KCl, ATP, and Ca²⁺). 11 μg of membranes were added to 12 μl buffer containing 40 mM MOPS, (pH 7.0), 20 mM MgCl₂, 20% Me₂SO, and 1.0 mM EGTA. Reactions are started by adding 1.0 μl of 3 mM P₁ containing trace amounts of ³²P₁. After a 10 min incubation at room temperature, the reactions were stopped with 7.5 μl LDS-PAGE sample loading buffer containing 3% LDS and the samples were processed as described above for the [γ-³²P]ATP-labeled samples.
CHAPTER 3—RESULTS

A. HYPOTHESIS 1: SERCA2a WITH BOUND PLB IS CATALYTICALLY INACTIVE

1. LARGE SCALE PRE-CROSS-LINKING OF N30C-PLB TO SERCA2a

SERCA2a was co-expressed with N30C-PLB in Sf21 insect cells, and the membranes were pre-cross-linked (N30C of PLB to Lys$^{328}$ of SERCA2a) on large scale over a Ca$^{2+}$ concentration range of 0–16.4 µM using the heterobifunctional cross-linker KMUS. After the cross-linking reactions were terminated, the membranes were pelleted, re-suspended, and stored in small aliquots at -80 °C until needed. The pre-cross-linked membranes were characterized by Western blotting with the anti-SERCA2a (2A7-A1) and anti-PLB (2D12) monoclonal antibodies. Total SERCA2a content in the membrane samples is shown in the upper panel of Fig. 16A, and the fraction of Ca$^{2+}$ pumps pre-cross-linked to PLB (PLB/SER) is shown in the lower panel. As predicted based upon previous results, as Ca$^{2+}$ concentration during the pre-cross-linking reaction was increased, N30C-PLB cross-linking to SERCA2a was inhibited. The plot of PLB/SER content in the membranes is shown in Fig. 16B. Maximal Ca$^{2+}$-ATPase activity of the pre-cross-linked membranes was then measured at saturating Ca$^{2+}$ concentration (50 µM Ca$^{2+}$). Percent maximal Ca$^{2+}$-ATPase activity was then plotted against PLB/SER for each pre-cross-linked sample (Fig. 16B). Importantly, maximal Ca$^{2+}$-ATPase activities were inversely proportional to PLB/SER levels detected in the membranes by Western blotting. This indicates that there is a tight correlation between PLB cross-linking to SERCA2a, and inhibition of Ca$^{2+}$-dependent hydrolysis of ATP by the Ca$^{2+}$ pump. This result demonstrates directly that when PLB is irreversibly bound to SERCA2a, the enzyme is catalytically inactive, and suggests that PLB immobilizes the enzyme in a Ca$^{2+}$-free state. Although this result shows that the overall catalytic cycle of SERCA2a is blocked by PLB binding, I went on to test whether the phosphorylation half-reactions
(forming $E1\sim P$ and $E2\sim P$ from $[\gamma-32P]ATP$ and $32P_i$, respectively) were also blocked by PLB binding

2. PHOSPHORYLATION OF PRE-CROSS-LINKED MEMBRANES WITH $[\gamma-32P]ATP$ AND $32P_i$ TO FROM $E1\sim P$ AND $E2\sim P$

The membrane samples containing N30C-PLB pre-cross-linked to SERCA2a over a range of $Ca^{2+}$ concentrations (0–16.4 µM) were phosphorylated under conditions favoring maximal phosphorylation by either $[\gamma-32P]ATP$ (at pH 7.0, in
buffer containing MgCl₂, KCl, and high Ca²⁺ concentration) or ³²Pᵢ, (at pH 7.0, in the presence Me₂SO and in the absence of KCl, ATP, and Ca²⁺) to from E₁⁻P and E₂⁻P, respectively. Autoradiographs showing formation of E₁⁻P and E₂⁻P are shown in Fig. 17A. N30C-PLB cross-linking to SERCA2a was inhibited as the Ca²⁺ concentration during the pre-cross-linking reaction was increased, and formation of both E₁⁻P and E₂⁻P increased as cross-linking was inhibited (Fig. 17A). The plots of the signals of formation of E₁⁻P and E₂⁻P were virtually super-imposable with each other and with the plot of maximal Ca²⁺-ATPase activity. Therefore, formation of the phosphorylated intermediates, E₁⁻P and E₂⁻P, and maximal Ca²⁺-ATPase activity was inversely proportional to PLB/SER content in the membranes (Fig. 17B). This inverse correlation between PLB cross-linked to SERCA2a and E₁⁻P and E₂⁻P formation corroborates the results of the Ca²⁺-ATPase assay, further supporting idea that SERCA2a with PLB bound is catalytically inactive.

**Figure 17. Effect of PLB Cross-Linking to SERCA2a on Maximal E₁⁻P and E₂⁻P Formation**

A, Autoradiogram shows maximal E₁⁻P and E₂⁻P formation from [γ-³²P]ATP and ³²Pᵢ, respectively, in membranes containing N30C-PLB and SERCA2a pre-cross-linked to SERCA2a at the Ca²⁺ concentration shown. B, Plot shows percent maximal E₁⁻P formation (purple x’s), E₂⁻P formation (green triangles), and Ca²⁺-ATPase activity (red circles) measured in the pre-cross-linked membranes, plotted against the percent maximal cross-linking signal PLB/SER (blue squares).
3. RESOLUTION OF PLB-FREE SERCA2a (CATALYTICALLY ACTIVE SERCA2a) FROM PLB/SER (CATALYTICALLY INACTIVE SERCA2a)

When cross-linked to PLB, SERCA2a undergoes a small mobility shift that causes it to run at a slightly higher molecular weight on acrylamide gels than PLB-free SERCA2a (6). I took advantage of this cross-linking induced mobility shift in order to resolve SERCA2a from PLB/SER, to definitively determine if PLB/SER is phosphorylatable by either $[\gamma^{32}\text{P}]\text{ATP}$ or $^{32}\text{P}_i$. Three specific pre-cross-linked samples containing ~100%, 50%, and 0% PLB/SER (0%, 50%, and 100% maximal Ca$^{2+}$-ATPase activity, respectively) were phosphorylated with either $[\gamma^{32}\text{P}]\text{ATP}$ or $^{32}\text{P}_i$, subjected to LDS-PAGE, and transferred to nitrocellulose. Autoradiographs of the radioactive signals of $E1\sim\text{P}$ and $E2\sim\text{P}$ formation were obtained. The $[\gamma^{32}\text{P}]\text{ATP}$ series was probed with 2A7-A1 (anti-SERCA2a antibody) and the $^{32}\text{P}_i$ series was probed with 2D12 (anti-PLB antibody) followed by alkaline phosphatase.

The cross-linking-induced mobility shift is clearly visible in the Western blot detecting the Ca$^{2+}$-ATPase protein (Fig. 18A, SERCA2a panel 1). The ~100% cross-linked sample ran as a single, slightly higher molecular weight band (PLB/SER). The ~50% cross-linked sample ran as a doublet with an upper band containing PLB/SER, and a slightly lower band containing PLB-free SERCA2a. In the ~0% cross-linked sample, the Ca$^{2+}$ pump ran as a single lower band (PLB-free SERCA2a). Consistent with this interpretation, in the 2D12 Western blot showing only SERCA2a cross-linked to PLB (Fig. 18A, PLB/SER panel 2), only the upper band of the SERCA2a doublet reacted with the anti-PLB antibody. These results confirm that PLB/SER and PLB-free SERCA2a run with slightly different mobility on acrylamide gels, forming two distinct bands. When the previously obtained autoradiographs showing formation of $E1\sim\text{P}$ and $E2\sim\text{P}$ (Fig. 18A, $E1\sim\text{P}$ panel 3, and $E2\sim\text{P}$ panel 4) were superimposed over the SERCA2a doublet, only the lower band containing PLB-free SERCA2a had been phosphorylated by either $[\gamma^{32}\text{P}]\text{ATP}$ or $^{32}\text{P}_i$. Therefore, whereas PLB-free SERCA2a readily underwent the kinetic half-reactions to form both $E1\sim\text{P}$ and $E2\sim\text{P}$, PLB/SER remained entirely unphosphorylatable under all conditions.
These results confirm the hypothesis that SERCA2a with PLB bound is entirely catalytically inactive.

Figure 18. Phosphorylation of Pre-Cross-Linked Membranes and LDS-PAGE Resolution of PLB-free SERCA2a from PLB/SER  N30C-PLB was pre-cross-linked to SERCA2a with KMUS at 0, 0.62, and 16.4 μM Ca^{2+} concentration and pelleted to remove all Ca^{2+} and excess cross-linker. Pre-cross-linked membranes were subjected to LDS-PAGE and Western blotting with the anti-SERCA2a (2A7-A1) and anti-PLB (2D12) antibodies, followed by alkaline phosphatase for protein visualization. Prior to LDS-PAGE, some of the pre-cross-linked membranes were phosphorylated under conditions favoring maximal phosphorylation by [γ-^{32}P]ATP or ^{32}P_{i}, and autoradiographs showing the radioactive signals of E1~P and E2-P formation were obtained. A, panel 1 shows the total SERCA2a content in membrane samples pre-cross-linked at the Ca^{2+} concentration shown. Panel 2 shows only SERCA2a cross-linked to PLB (PLB/SER). Panel 3 shows the radioactive signal of E1~P formation from [γ-^{32}P]ATP. Panel 4 shows the radioactive signal of E2-P formation by ^{32}P_{i}. Superimposition of panel 3 over panel 1 shows that only the lower band of the SERCA2a doublet was phosphorylated by [γ-^{32}P]ATP to form E1~P. Superimposition of panel 4 over panel 2 shows that only PLB-free SERCA2a was phosphorylated by ^{32}P_{i} to form E2-P. B, Close-up showing PLB/SER, total SERCA2a (SERCA2a), and maximal phosphorylation by [γ-^{32}P]ATP (E1~P) of the membrane sample pre-cross-linked at 0.62 μM Ca^{2+} concentration.
B. HYPOTHESIS 2: PLB DECREASES THE Ca$^{2+}$ AFFINITY OF SERCA2a BY COMPETING WITH Ca$^{2+}$ FOR BINDING TO THE ENZYME

1. CO-EXPRESSİON OF SERCA2a WITH N30C-PLB, PLB3 AND PLB4

Using the Baculovirus expression system, SERCA2a was expressed alone in Sf21 insect cells, or co-expressed with N30C-PLB, PLB3, and PLB4. Protein expression levels in the membrane samples were determined by Western blotting with the anti-SERCA2a (2A7-A1) and anti-PLB (2D12) monoclonal antibodies. **Fig. 19** shows that similar levels of SERCA2a and PLB (± 20%) were co-expressed in the different membrane preparations. It should be noted that under the conditions used for SDS-PAGE (7% SDS), all three of the PLB mutants were entirely monomeric.

![Figure 19. Amido Black Staining and Immunoblot of SERCA2a Co-Expressed with N30C-PLB, PLB3, and PLB4. SERCA2a and N30C-PLB, PLB3, or PLB4 were co-expressed in Sf21 insect cells. Membrane samples (11 µg) were then subjected to SDS-PAGE, transferred to nitrocellulose, and the nitrocellulose sheet stained with Amido Black (left panel). The nitrocellulose sheet was then cut in half, and the upper portion was probed with the anti-SERCA2a antibody, 2A7-A1, and the lower half was probed with the anti-PLB antibody, 2D12, followed by 125I-protein A (right panel). Control experiments showed that the 2D12 antibody bound with equal strength to all three PLB mutants (data not shown). From Akin, B.L., Chen, Z., and Jones, L.R (2010) *J.Biol.Chem.* 285, 28540-28552.](image-url)
2. \( \text{Ca}^{2+} \) ACTIVATION OF \( \text{Ca}^{2+} \)-ATPASE ACTIVITY AND \( \text{Ca}^{2+} \) INHIBITION OF PLB CROSS-LINKING TO SERCA2a

\( \text{Ca}^{2+} \)-stimulation of \( \text{Ca}^{2+} \)-ATPase activity of SERCA2a expressed alone and SERCA2a co-expressed with N30C-PLB, PLB3, and PLB4 was measured (Fig. 20). Based upon Western blots, \( \text{Ca}^{2+} \)-ATPase activities were corrected for variability in expression levels between preparations. SERCA2a expressed alone exhibited typical ATP hydrolysis, with half-maximal activation of \( \text{Ca}^{2+} \)-ATPase activity occurring at 0.16 µM \( \text{Ca}^{2+} \) (\( K_{\text{Ca}} = 0.16 \) µM), and maximal enzyme activity reached at the saturating \( \text{Ca}^{2+} \) concentration of 1-2 µM (Fig. 4A and Table 1). At \( \text{Ca}^{2+} \) concentrations greater than 2 µM, substantial back inhibition of the enzyme by \( \text{Ca}^{2+} \) was observed (58, 59). Co-expression of SERCA2a with N30C-PLB increased the \( K_{\text{Ca}} \) value for enzyme activation approximately 2-fold, from 0.16 µM to 0.33 µM, with little or no effect on the \( V_{\text{max}} \) of the enzyme measured at 1-2 µM \( \text{Ca}^{2+} \) (Fig. 20A and Table 1). The effect of N30C-PLB on enzyme activity observed here is identical to the effect of wild-type PLB reported previously (27). In contrast to N30C-PLB, PLB3 and PLB4 had large effects on both the \( K_{\text{Ca}} \) of enzyme activation and on \( V_{\text{max}} \).

**TABLE 1**

\( K_{\text{Ca}} \) values (µM) for \( \text{Ca}^{2+} \)-ATPase activation and \( E1-P \) formation, and \( K_{i} \) values (µM) for \( \text{Ca}^{2+} \) inhibition of PLB cross-linking

SERCA2a was expressed alone or co-expressed with N30C-PLB (N30C), PLB3 or PLB4 in insect cell microsomes. \( \text{Ca}^{2+} \)-ATPase activities and cross-linking were determined under identical conditions in the presence and absence of the anti-PLB antibody, 2D12, as described in the text. The *\( K_{\text{Ca}} \) values shown in parentheses were calculated based upon the maximal activity determined for SERCA2a expressed alone (see Results). Results are means ± S.E. of 4-6 determinations.

<table>
<thead>
<tr>
<th>Protein Expressed</th>
<th>( K_{\text{Ca}} ) values</th>
<th>( K_{i} ) values</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>( \text{Ca}^{2+} ) ATPase activity</td>
<td>( E1-P )</td>
</tr>
<tr>
<td></td>
<td>- 2D12</td>
<td>+ 2D12</td>
</tr>
<tr>
<td>SERCA2a</td>
<td>0.16 ± 0.01</td>
<td>0.16 ± 0.02</td>
</tr>
<tr>
<td>+ N30C</td>
<td>0.33 ± 0.02</td>
<td>0.19 ± 0.00</td>
</tr>
<tr>
<td>(*0.35 ± 0.02)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ PLB3</td>
<td>0.53 ± 0.05</td>
<td>0.26 ± 0.02</td>
</tr>
<tr>
<td>(*0.88 ± 0.03)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ PLB4</td>
<td>0.70 ± 0.04</td>
<td>0.36 ± 0.01</td>
</tr>
<tr>
<td>(*1.49 ± 0.02)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The $K_{Ca}$ values were increased 3.3-fold (0.53 $\mu$M $Ca^{2+}$) and 4.4-fold (0.70 $\mu$M $Ca^{2+}$) by PLB3 and PLB4, respectively, when calculated based on the highest $Ca^{2+}$-ATPase activity achieved by SERCA2a co-expressed with these two mutants, which occurred at 2 $\mu$M $Ca^{2+}$. It should be noted that at 2 $\mu$M $Ca^{2+}$ concentration, the $V_{\text{max}}$ of the enzyme was inhibited by approximately 30% by both PLB3 and PLB4, relative to the same amount of SERCA2a expressed alone or with N30C-PLB (Fig. 20A). Nevertheless, complete reversal of $Ca^{2+}$-ATPase inhibition by PLB3 and PLB4 did occur at much higher $Ca^{2+}$ concentrations (in the range of 100 - 200 $\mu$M), $Ca^{2+}$ concentrations at which significant back inhibition of the enzyme occurred. Thus, in $Ca^{2+}$-ATPase assays, SERCA2a co-expressed with PLB3 or PLB4 can never achieve its maximal turnover rate, even though very high $Ca^{2+}$ concentrations do completely reverse $Ca^{2+}$-ATPase inhibition by the supershifters. To correct for back inhibition of the enzyme by $Ca^{2+}$, we also calculated the $K_{Ca}$ values for SERCA2a co-expressed with N30C-PLB, PLB3, and PLB4 using the $V_{\text{max}}$ value for SERCA2a expressed alone (Fig. 20A, grey lines intersecting the abscissa) (*$K_{Ca}$ values). When calculated by this method, the *$K_{Ca}$ values for SERCA2a co-expressed with N30C-PLB, PLB3, and PLB4 were 0.35 $\mu$M, 0.88 $\mu$M, and 1.49 $\mu$M, respectively (Table 1, parentheses). These corrected *$K_{Ca}$ values indicate that 2.2-fold, 5.5-fold, and 9.3-fold higher $Ca^{2+}$ concentrations are required to half-maximally activate SERCA2a co-expressed with N30C-PLB, PLB3, and PLB4, respectively.

Next, the relative binding affinities of the PLB mutants for SERCA2a were estimated by measuring $Ca^{2+}$ inhibition of PLB cross-linking to the enzyme. All three PLB mutants cross-linked only to the cardiac $Ca^{2+}$ pump expressed in insect cell membranes, and all cross-linking results reported here depict the PLB monomer bound to SERCA2a (21) (see EXPERIMENTAL PROCEDURES). In the absence of $Ca^{2+}$, strong cross-linking of all three PLB mutants to Lys$^{328}$ of SERCA2a was observed, and cross-linking was completely eliminated by increasing $Ca^{2+}$ concentration (Fig. 20B). The $K_{i}$ values for $Ca^{2+}$ inhibition of N30C-PLB, PLB3, and PLB4 cross-linking to SERCA2a were 0.35, 0.88, and 1.8 $\mu$M $Ca^{2+}$, respectively (Table 1). These $K_{i}$ values for $Ca^{2+}$ inhibition of cross-linking agree closely with the *$K_{Ca}$ values determined for half-maximal activation of $Ca^{2+}$-ATPase activity. This
Figure 20. Ca\textsuperscript{2+} activation of Ca\textsuperscript{2+}-ATPase Activity and Ca\textsuperscript{2+} Inhibition of Cross-linking
SERCA2a was expressed alone or co-expressed with N30C-PLB, PLB3, or PLB4 in Sf21 cells and SERCA2a and PLB expression levels were determined by Western blotting. Panel A depicts Ca\textsuperscript{2+}-ATPase activities measured as described under "EXPERIMENTAL PROCEDURES". Enzyme activities were normalized to expression levels of SERCA2a expressed alone. The grey line intersecting the ordinate indicates the 50% \(V_{\text{max}}\) value determined for SERCA2a expressed alone. Panel B shows cross-linking of the PLB mutants to SERCA2a determined under identical conditions as the Ca\textsuperscript{2+}-ATPase assay. Aliquots were taken from the Ca\textsuperscript{2+}-ATPase assay and cross-linked for 15 sec with 1mM KMUS at 37°C. Samples were then subjected to SDS-PAGE and immunoblotting with the anti-PLB antibody, 2D12. Protein bands in the upper panel show SERCA2a cross-linked with the PLB monomer. PLB cross-linking is quantified in the graph below. The graph in Panel C was derived from the data in panels A and B. Percent maximal PLB cross-linking to SERCA2a (determined in the absence of Ca\textsuperscript{2+}) was calculated at each Ca\textsuperscript{2+} concentration for each PLB mutant, and then plotted against the percent inhibition of Ca\textsuperscript{2+}-ATPase activity by PLB obtained at the same Ca\textsuperscript{2+} concentration. The percent inhibition of Ca\textsuperscript{2+}-ATPase activity by PLB at each Ca\textsuperscript{2+} concentration was calculated by dividing the Ca\textsuperscript{2+}-ATPase activity of membranes expressing SERCA2a plus PLB by the Ca\textsuperscript{2+}-ATPase activity of membranes expressing SERCA2a alone, and multiplying by 100. From Akin, B.L., Chen, Z., and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552.
demonstrates a strong correlation between PLB binding to $E_2$, and decreased Ca$^{2+}$ affinity of SERCA2a determined by the Ca$^{2+}$-ATPase assay. This conclusion is strengthened by plotting the percent maximal PLB cross-linking to SERCA2a (determined at each Ca$^{2+}$ concentration covering the range from 0.12 µM to 200 µM), against the percent inhibition of Ca$^{2+}$-ATPase activity determined at the same Ca$^{2+}$ concentrations (Fig. 20C). For all three PLB mutants, regardless of inhibitory strength, there was strong correlation ($R^2 = 0.97$) between extent of PLB cross-linking to SERCA2a and degree of enzyme inhibition. These data strongly suggest that SERCA2a with bound PLB is catalytically inactive, and point to competitive binding of PLB and Ca$^{2+}$ as the mechanism of enzyme inhibition.

Figure 21. PLB Effect on Formation of the Phosphorylated Enzyme Intermediate  
Ca$^{2+}$ stimulation of phosphoenzyme formation by [$\gamma$$^{32}$P]ATP was determined for SERCA2a expressed alone, and co-expressed with each PLB mutant. The upper panel is the autoradiograph depicting the radioactive phosphoenzyme, and results are plotted below (dark lines). For comparison, Ca$^{2+}$ effects on N30C-PLB (squares), PLB3 (circles), and PLB4 (triangles) cross-linking to SERC2a are also displayed (grey lines), taken from Fig. 20B. From Akin, B.L., Chen, Z., and Jones, L.R (2010) *J.Biol.Chem*. **285**, 28540-28552.
3. **Ca\(^{2+}\) STIMULATION OF E1-P FORMATION CORRELATED WITH Ca\(^{2+}\) INHIBITION OF PLB CROSS-LINKING TO SERCA2a**

Consistent with the Ca\(^{2+}\)-ATPase results, when Ca\(^{2+}\) stimulation of phosphoenzyme formation from ATP was monitored similar shifts in \(K_{Ca}\) by the different PLB mutants were observed (Fig. 21). The \(K_{Ca}\) for SERCA2a expressed alone was 0.11 \(\mu M\), whereas when co-expressed with N30C-PLB, PLB3, and PLB4, the \(K_{Ca}\) values were 0.36 \(\mu M\), 1.16 \(\mu M\), and 2.05 \(\mu M\) (Table 1), respectively. These \(K_{Ca}\) values are nearly identical to the \(K_i\) values determined for Ca\(^{2+}\) inhibition of PLB cross-linking (grey lines). These results are particularly significant due to the fact that back inhibition of the Ca\(^{2+}\) pump is not a factor when phosphoenzyme formation from \([\gamma-^{32}P]ATP\) is monitored, therefore, no correction for loss of enzyme turnover at high Ca\(^{2+}\) concentration is required when \(K_{Ca}\) values are estimated by this method.

4. **THE EFFECT OF 2D12 ON Ca\(^{2+}\)-ATPASE ACTIVITY AND PLB CROSS-LINKING**

The anti-PLB monoclonal antibody, 2D12, recognizes residues 7-13 of PLB and reverses PLB inhibition of the Ca\(^{2+}\)-pump by physically disrupting PLB binding to SERCA2a (6). 2D12 reverses enzyme inhibition by wild-type PLB (38) and N30C-PLB virtually completely (6), but only partially reverses the effects of several supershifting PLB mutants on Ca\(^{2+}\)-ATPase activity (58). This suggests that the PLB supershifters may bind more tightly to the Ca\(^{2+}\) pump than wild-type PLB or N30C-PLB, but this has not been demonstrated directly. Therefore, in order to confirm tighter binding of the PLB supershifters, and to show that the Ca\(^{2+}\) affinity of the enzyme is restored commensurate with dissociation of PLB from SERCA2a, we measured the effect of 2D12 on N30C-PLB, PLB3, and PLB4 cross-linking to SERCA2a simultaneously with Ca\(^{2+}\)-ATPase activity.

Ca\(^{2+}\)-ATPase activity of SERCA2a co-expressed with N30C-PLB, PLB3, and PLB4 was measured in the presence of 8 \(\mu g\) of 2D12 (4.44 \(\mu M\)), a concentration sufficient to completely saturate PLB (Fig. 22, A-C). As shown previously (6), the
2D12 antibody restored the Ca$^{2+}$ affinity of SERCA2a co-expressed with N30C-PLB nearly completely, decreasing the $K_{Ca}$ from 0.33 to 0.19 $\mu$M Ca$^{2+}$, compared to 0.16 $\mu$M Ca$^{2+}$ for SERCA2a expressed alone (Table 1). On the other hand, 2D12 only partially restored the Ca$^{2+}$ affinity of the enzyme co-expressed with the superinhibitory mutants PLB3 and PLB4, shifting the $K_{Ca}$ values from 0.53 to 0.26 $\mu$M for PLB3, and from 0.70 to 0.36 $\mu$M for PLB4. Also, whereas 2D12 had little or no effect on the $V_{max}$ of the enzyme co-expressed with N30C-PLB, 2D12 increased the $V_{max}$ of the enzyme co-expressed with PLB3 and PLB4 significantly. In the
presence of the antibody at 1-2 µM Ca\(^{2+}\), Ca\(^{2+}\) pumps co-expressed with PLB3 and PLB4 achieved 80 - 95% of the maximal activity of Ca\(^{2+}\) pumps expressed alone.

The effects of 2D12 on PLB cross-linking during the same assay are shown in Fig. 22, D-F. Consistent with previous results, 2D12 inhibited cross-linking of N30C-PLB to the Ca\(^{2+}\) pump nearly completely in the absence of Ca\(^{2+}\) and at all Ca\(^{2+}\) concentrations tested (6). This explains why Ca\(^{2+}\) pump inhibition by N30C-PLB is 30% or less at each Ca\(^{2+}\) concentration tested when Ca\(^{2+}\)-ATPase activity was measured in the presence of 2D12. On the other hand, PLB3 and PLB4 cross-linking to SERCA2a in the absence of Ca\(^{2+}\) was substantially reduced by addition of 2D12, but not eliminated altogether (25% and 53% maximal cross-linking persisted, respectively). Even in the presence of the antibody, Ca\(^{2+}\) concentrations of 1 µM or higher were required to completely dissociate PLB3 and PLB4 from the Ca\(^{2+}\) pump (E and F). These cross-linking results agree well with the results of the Ca\(^{2+}\)-ATPase assays, which showed that the enzyme was significantly inhibited by PLB3 and PLB4 even in the presence of 2D12. In experiments not shown, the binding affinity of PLB for 2D12 was determined to be 0.1 µM. Therefore, we conclude that the binding affinities of PLB3 and PLB4 for SERCA2a must be very high, at least within the range at which PLB binds 2D12.

5. THE EFFECT OF Ca\(^{2+}\) ON PLB CROSS-LINKING TO D351A

In order to test directly for competition between PLB and Ca\(^{2+}\) for binding to SERCA2a, we took advantage of the Ca\(^{2+}\)-pump mutant, D351A. During catalysis, Asp\(^{351}\) is phosphorylated by ATP to form the high-energy acylphosphoprotein intermediate, \(E1\sim P\cdot Ca_2\) (Fig. 4). Replacement of aspartic acid at this position renders the enzyme catalytically inactive (53, 54). Although inactive at the site of ATP hydrolysis, D351A retains the ability to bind Ca\(^{2+}\) and maintains the thermodynamic equilibrium between \(E1\) and \(E2\) (53, 55, 56). Therefore, if PLB acts by stabilizing \(E2\) and shifting the \(E1\sim Ca_2 \leftrightarrow E2\cdot PLB\) equilibrium away from \(E1\), then this effect should be fully reproducible with D351A. The advantage of using D351A for these experiments is that enzyme turnover is prevented; hence the system is at equilibrium.
Figure 23. **Ca\(^{2+}\) effect on PLB cross-linking to D351A**  

\(\text{Ca}^{2+}\) inhibition of N30C-PLB cross-linking to wild-type SERCA2a (A) and D351A (B) was determined under Ca\(^{2+}\)-ATPase assay conditions, as described under "EXPERIMENTAL PROCEDURES." PLB/SER designates the PLB monomer cross-linked to the Ca\(^{2+}\) pump at 110 kDa, and free PLB monomers (PLB\(_1\)) and dimers (PLB\(_2\)) are visible below at 6 kDa and 12 kDa, respectively. The full autoradiographs are shown, demonstrating the highly specific cross-linking reaction; PLB cross-linked exclusively to expressed wild-type SERCA2a or D351A in Sf21 membranes. C, Graph of \(\text{Ca}^{2+}\) inhibition of N30C-PLB cross-linking to wild-type SERCA2a and D351A. D, \(\text{Ca}^{2+}\) inhibition of N30C-PLB, PLB3, and PLB4 cross-linking to D351A. \(K_i\) values for \(\text{Ca}^{2+}\) inhibition of cross-linking to D351A are listed in RESULTS. From **Akin, B.L.**, Chen, Z., and Jones, L.R (2010) *J.Biol.Chem.* **285**, 28540-28552.
with respect to Ca\(^{2+}\) binding (Fig. 4). Consistent with previous results with SERCA1a, we first confirmed that the D351A mutant made from SERCA2a exhibited no Ca\(^{2+}\)-ATPase activity, and was not phosphorylatable by [\(\gamma\)\(^{32}\)P]ATP to form E1\(\sim\)P (54), nor by Pi to form E2\(\sim\)P (53) (data not shown).

Next, the affinity of D351A for Ca\(^{2+}\) was compared to that of wild-type SERCA2a by measuring Ca\(^{2+}\)-inhibition of N30C-PLB cross-linking. In the absence of Ca\(^{2+}\), D351A and wild-type SERCA2a bound comparable amounts of N30C-PLB (Fig. 23, A and B). However, a strikingly lower Ca\(^{2+}\) concentration was sufficient to disrupt N30C-PLB cross-linking to D351A \((K_i = 18 \text{ nM})\) compared to wild-type SERCA2a \((K_i = 280 \text{ nM})\) (Fig. 23C). In fact, the Ca\(^{2+}\) affinity of D351A determined by this method (18 nM) is approximately 9-fold higher than the Ca\(^{2+}\) affinity of wild-type SERCA2a estimated by Ca\(^{2+}\)-ATPase assay \((0.16 \mu\text{M} \text{ in Table 1})\). Assuming that N30C-PLB decreases the Ca\(^{2+}\) affinity of D351A by approximately 2-fold (as it does for wild-type SERCA2a), the Ca\(^{2+}\) affinity of D351A expressed alone is likely even higher than this, in the range of 10 nM. This remarkably high Ca\(^{2+}\) affinity for D351A was first reported by MacIntosh et al. (55), but subsequently not confirmed (56) (see DISCUSSION). Fig. 23A also points out the highly specific nature of the PLB to SERCA2a cross-linking reaction, with PLB cross-linking exclusively to the Ca\(^{2+}\) pump protein expressed in Sf21 membranes.

Ca\(^{2+}\)-inhibition of N30C-PLB, PLB3, and PLB4 cross-linking to D351A was then measured (Fig. 23D). As predicted from results with wild-type SERCA2a, progressively higher concentrations of Ca\(^{2+}\) were also required to dissociate N30C-PLB \((K_i = 18 \pm 3 \text{ nM})\), PLB3 \((K_i = 131 \pm 25 \text{ nM})\) and PLB4 \((K_i = 234 \pm 23 \text{ nM})\) from D351A (means \(\pm\) S.E from 4 determinations). Fig. 23D demonstrates unambiguously that N30C-PLB and the supershifting PLB mutants, PLB3 and PLB4, inhibit Ca\(^{2+}\) binding to D351A. This result is consistent with the hypothesis that PLB competes with Ca\(^{2+}\) for binding to SERCA2a.
C. HYPOTHESIS 3: PLB BINDS EXCLUSIVELY TO THE E2-ATP CONFORMATION OF THE Ca\(^{2+}\) PUMP

1. THE EFFECT OF TG AND NUCLEOTIDES ON PLB CROSS-LINKING TO WILD-TYPE SERCA2a

To investigate the specific conformation of the Ca\(^{2+}\) pump that binds PLB, and confirm the relative binding affinities of the PLB mutants for SERCA2a, the effects of TG and nucleotides on PLB cross-linking to SERCA2a were measured in the absence of Ca\(^{2+}\). It was shown previously that N30C-PLB binds preferentially to the E2 state of SERCA2a stabilized by bound nucleotide (21), and that TG antagonizes formation of this state.

When measured in the absence of ATP, TG potently inhibited the cross-linking of all three PLB mutants to SERCA2a (Fig. 24, A and B). The \(K_i\) values for TG inhibition of N30C-PLB, PLB3, and PLB4 cross-linking to SERCA2a were low and similar (0.07 \(\mu\)M, 0.07 \(\mu\)M and 0.10 \(\mu\)M, respectively) (Table 2), and within range of Ca\(^{2+}\) pumps present within the reaction tubes (\(\sim\) 0.3 \(\mu\)M). Thus, TG bound virtually stoichiometrically to the Ca\(^{2+}\) pump (34, 35), whether co-expressed with N30C-PLB, PLB3, or PLB4. However, addition of 3 mM ATP to the assay tubes dramatically increased the concentration of TG required to inhibit PLB3 and PLB4 cross-linking to

<table>
<thead>
<tr>
<th>Protein expressed</th>
<th>(K_{TG}) values ((\mu)M)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No Nuc</td>
</tr>
<tr>
<td>SERCA2a</td>
<td></td>
</tr>
<tr>
<td>+ N30C</td>
<td>0.07 ± 0.02</td>
</tr>
<tr>
<td>+ PLB3</td>
<td>0.07 ± 0.01</td>
</tr>
<tr>
<td>+ PLB4</td>
<td>0.10 ± 0.01</td>
</tr>
<tr>
<td>D351A</td>
<td></td>
</tr>
<tr>
<td>+ N30C</td>
<td>0.07 ± 0.005</td>
</tr>
<tr>
<td>+ PLB3</td>
<td>0.08 ± 0.02</td>
</tr>
<tr>
<td>+ PLB4</td>
<td>0.11 ± 0.02</td>
</tr>
</tbody>
</table>
SERCA2a. The $K_i$ values (Fig. 24, A and C) increased from 0.07 µM to 4.9 µM for PLB3, and from 0.10 µM to 7.8 µM for PLB4, whereas for N30C-PLB, addition of ATP only increased $K_i$ value from 0.07 µM to 0.23 µM (Table 2). That is a remarkable 70-fold (PLB3) and 78-fold (PLB4) decrease in TG binding affinity induced by ATP when supershifting PLB mutants are present. It should be pointed out that the concentration of PLB present in the reaction tubes was approximately 1.0 µM, which is considerably lower than the concentration of TG required to significantly inhibit cross-linking of PLB3 and PLB4 to the Ca$^{2+}$-ATPase in the presence of ATP (Fig. 24C). Thus the affinity of the two PLB supershifters for $E_2\cdot$ATP must be even greater than the affinity of TG for $E_2\cdot$ATP, which is within the nanomolar range or lower (34, 35). The same results with PLB3 or PLB4 were obtained whether membranes were pre-incubated with TG for 5 min or 60 min prior

**Figure 24. TG effect on PLB cross-linking** A, autoradiographs showing concentration dependence of TG inhibition N30C-PLB, PLB3, and PLB4 cross-linking to SERCA2a, measured in the absence (-ATP) and presence (+ATP) of 3 mM ATP. B and C, graphs of TG inhibition of cross-linking, determined in the absence and presence of 3 mM ATP, respectively. From Akin, B.L., Chen, Z., and Jones, L.R (2010) J. Biol. Chem. 285, 28540-28552.
to initiation of the cross-linking reactions with KMUS, indicating that the supershifters prevent formation of a dead-end complex by TG (34) under these conditions.

Like ATP, ADP also dramatically increased the $K_i$ value for TG inhibition of PLB cross-linking to the Ca$^{2+}$-ATPase, whereas AMP had no significant effect (Fig. 25A demonstrated with PLB4). These results confirm previous findings that both ATP and ADP, but not AMP, stabilize the $E2$ state that favors PLB binding (21). We then measured the binding affinity of SERCA2a for ATP determined at different

Figure 25. Nucleotide Effect on PLB4 Cross-Linking to Wild-Type SERCA2a and D351A A, effect of 3 mM AMP, ADP, ATP, and no added nucleotide (Con) on PLB4 cross-linking to wild-type SERCA2a. TG concentrations were varied as indicated. B, ATP stimulation of PLB4 cross-linking to wild-type SERCA2a, determined at different TG concentrations. ATP concentrations were varied as indicated. C, ATP stimulation of PLB4 cross-linking to D351A, determined at different TG concentrations. From Akin, B.L., Chen, Z., and Jones, L.R (2010) *J.Biol.Chem.* 285, 28540-28552.
concentrations of TG (Fig. 25B). Successively higher concentrations of ATP were required to stimulate PLB4 cross-linking to the Ca\(^{2+}\)-ATPase when the concentration of TG was increased. In the absence of TG, the affinity of SERCA2a for ATP was 9 µM; in the presence of 6.4 µM TG, the affinity of the enzyme for ATP was decreased 10-fold, to approximately 100 µM (Table 3). These \(K_{ATP}\) values for SERCA2a measured in the absence of Ca\(^{2+}\) agree well with those in previous reports, and confirm for SERCA2a, that TG significantly reduces the affinity of the enzyme for ATP at the modulatory nucleotide-binding site (60-62). Collectively, these results demonstrate that PLB binds to a single conformation of SERCA2a, \(E_2\) with bound nucleotide, and this state is distinct from the \(E_2\) conformation binding TG (see DISCUSSION), all of which is consistent with the hypothesis that PLB binds exclusively to the \(E_2\cdot\text{ATP}\) conformation of the Ca\(^{2+}\) pump.

2. THE EFFECTS OF TG AND NUCLEOTIDES ON PLB CROSS-LINKING TO D351A-SERCA2a

Similar nucleotide effects on PLB binding to D351A were noted. The \(K_i\) values for TG inhibition of cross-linking of all three PLB mutants to D351A were low and similar when assessed in the absence of ATP, but dramatically increased for PLB3 and PLB4 when ATP was included (Table 2). TG also substantially decreased the ATP binding affinity of D351 (Fig. 25C and Table 3). Interestingly, the affinity of D351A for ATP was only about 2-fold greater than the affinity of wild-type

<table>
<thead>
<tr>
<th>TG (µM)</th>
<th>(K_{ATP}) values (µM) for ATP stimulation of PLB4 cross-linking to the Ca(^{2+})-ATPase, determined at different TG concentrations</th>
<th>(K_{ATP}) values are the ATP concentration at which cross-linking was half-maximal as determined directly from the plot. Results are the means ± S.E. of 3-5 determinations.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(K_{ATP}) values</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(K_{ATP}) values</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SERCA2a</td>
<td>D351A</td>
</tr>
<tr>
<td>0</td>
<td>9.0 ± 1.5</td>
<td>4.0 ± 0.9</td>
</tr>
<tr>
<td>0.23</td>
<td>34.0 ± 7.8</td>
<td>15.3 ± 2.7</td>
</tr>
<tr>
<td>2.11</td>
<td>65.0 ± 10.4</td>
<td>24.0 ± 1.5</td>
</tr>
<tr>
<td>6.41</td>
<td>103 ± 12.0</td>
<td>46.0 ± 4.0</td>
</tr>
</tbody>
</table>
SERCA2a for ATP (Table 3), which is substantially lower than the ATP binding affinity of D351A made from SERCA1a (55, 56) (see DISCUSSION).

3. THE EFFECTS OF VANADATE ON PLB CROSS-LINKING TO SERCA2a

According to results above with TG, the binding affinities of N30C-PLB and the supershifters for the E2 state of SERCA2a are much higher than previously predicted (51). Therefore, to confirm these surprising results, we used a second lower affinity Ca$^{2+}$ pump inhibitor, vanadate, to estimate the binding affinities of the PLB mutants for SERCA2a. Vanadate inhibits the Ca$^{2+}$-ATPase with micromolar affinity, and like TG is proposed to bind preferentially to the nucleotide-free, E2 conformation.

Figure 26. Vanadate Effect on PLB Cross-Linking to SERCA2a A, autoradiographs showing concentration dependence of vanadate inhibition N30C-PLB, PLB3, and PLB4 cross-linking to SERCA2a, measured in the absence (-ATP) and presence (+ATP) of 36 µM ATP. B and C, graphs of vanadate inhibition of cross-linking, determined in the absence and presence of 36 µM ATP, respectively. From Akin, B.L., Chen, Z., and Jones, L.R (2010) J.Biol.Chem. 285, 28540-28552.
of the Ca\(^{2+}\) pump (63). **Fig. 26** shows that in the absence of Ca\(^{2+}\) and ATP, vanadate inhibited cross-linking of all three PLB mutants to SERCA2a. However, significantly higher concentrations of vanadate were required to inhibit PLB3 (\(K_i = 46 \ \mu\text{M}\)) and PLB4 (\(K_i = 380 \ \mu\text{M}\)) cross-linking to SERCA2a, relative to N30C-PLB (\(K_i = 1.6 \ \mu\text{M}\), **Fig. 26B**). Moreover, maximal cross-linking of PLB3 and PLB4 to SERCA2a could only be inhibited by 80% and 60% at 1 mM vanadate, the highest concentration tested. When 36 \(\mu\text{M}\) ATP was included in the buffer, the \(K_i\) for vanadate inhibition of N30C-PLB cross-linking to SERCA2a was increased 125-fold, from 1.6 \(\mu\text{M}\) (no nucleotide) to 200 \(\mu\text{M}\) vanadate (36 \(\mu\text{M}\) ATP), and cross-linking of PLB3 and PLB4 to SERCA2a became nearly completely vanadate resistant (**Fig. 26C**). At 3 mM ATP, vanadate failed to inhibit cross-linking of any PLB mutant to the Ca\(^{2+}\)-ATPase (data not shown). Thus, results with vanadate also show that PLB binds with surprisingly high affinity to the \(E2\) state of SERCA2a when nucleotide is present.
CHAPTER 4—DISCUSSION

The purpose of this dissertation research was to investigate the molecular mechanism of PLB regulation of Ca\(^{2+}\)-ATPase activity. Three hypotheses were tested, each one specifically designed to address a fundamental point in the mechanism of PLB action. Using chemical cross-linking in conjunction with PLB mutants of increasing inhibitory function, new insights were gained on the catalytic activity of PLB-bound SERCA2a, the effect of PLB on the Ca\(^{2+}\) affinity and \(V_{\text{max}}\) of the enzyme, and the specific conformation of SERCA2a required for PLB binding.

A. HYPOTHESIS 1: SERCA2a WITH PLB BOUND IS CATALytically INACTIVE

PLB inhibits Ca\(^{2+}\)-ATPase activity of SERCA2a by decreasing apparent Ca\(^{2+}\) affinity of the enzyme, and PLB effects on Ca\(^{2+}\) affinity are reversed by phosphorylation of PLB by PKA or CaMKII, and by micromolar Ca\(^{2+}\) concentration (2, 3). However, whether disinhibition of the Ca\(^{2+}\) pump requires complete dissociation of PLB from the SERCA2a has remained unclear. In a study in which fluorescence resonance energy transfer was used to monitor protein-protein interactions between PLB and the Ca\(^{2+}\)-ATPase, Mueller et al. concluded that the affinity of PLB for the Ca\(^{2+}\) pump is so high that under physiological conditions PLB essentially never dissociates (36). The authors suggested Ca\(^{2+}\)-induced structural changes in SERCA cause significant conformational rearrangements in PLB, but PLB remains tightly bound nonetheless (36). Similarly, using frequency-domain fluorescence spectroscopy to monitor interactions between PLB and the Ca\(^{2+}\) pump, Li et al. concluded that dissociation of PLB is not requisite for Ca\(^{2+}\) pump activation (37).

In contrast to the findings of Mueller et al. (36) and Li et al. (37), here it was shown definitively that SERCA2a with PLB irreversibly bound (PLB/SER) is catalytically inactive (Figs. 15-17). Whereas PLB-free SERCA2a readily underwent the kinetic half-reactions to form both \(E1\)-P and \(E2\)-P, SERCA2a with PLB bound was completely devoid of catalytic activity and entirely unphosphorylatable under all
conditions (Figs. 16 and 17). From these results we conclude that when PLB is bound, SERCA2a is immobilized in the Ca\(^{2+}\)-free E2 state, and in order for the catalytic cycle to resume, PLB must first completely dissociate from the enzyme. Therefore, by mass action PLB reduces the fraction of Ca\(^{2+}\)-pumps available to bind and transport Ca\(^{2+}\), which would be manifested as a decrease in the apparent Ca\(^{2+}\) affinity of the enzyme, the hallmark of PLB regulation of SERCA2a (2, 3).

**B. HYPOTHESIS 2: PLB DECREASES THE Ca\(^{2+}\) AFFINITY OF SERCA2a BY COMPETING WITH Ca\(^{2+}\) FOR BINDING TO THE ENZYME**

1. **PLB SUPERSHIFTERES REVEAL COMPETITIVE BINDING OF PLB AND Ca\(^{2+}\) TO SERCA2a**

   It is generally accepted that PLB decreases the apparent Ca\(^{2+}\) affinity of the Ca\(^{2+}\)-ATPase, while having little or no effect on the \(V_{\text{max}}\) of the enzyme measured at saturating Ca\(^{2+}\) concentration (2, 3). However, whether PLB increases the \(K_{\text{Ca}}\) of Ca\(^{2+}\)-ATPase activation by decreasing the actual Ca\(^{2+}\) binding affinity of the enzyme (21, 23, 44, 64), or by affecting one or more catalytic steps in the reaction cycle (36-41) has remained unclear. Here this question was addressed directly, using cross-linkable PLB mutants of increasing inhibitory potency (PLB4 > PLB3 > N30C-PLB). We showed that successively higher concentrations of Ca\(^{2+}\) were required to both activate the enzyme co-expressed with N30C-PLB, PLB3, and PLB4 and to dissociate N30C-PLB, PLB3, and PLB4 from the Ca\(^{2+}\) pump (Figs. 20 and 21). Moreover, there was a direct correlation between the degree of PLB binding to SERCA2a and the extent of PLB inhibition of Ca\(^{2+}\)-ATPase activity at all Ca\(^{2+}\) concentrations tested with all three PLB mutants (Fig. 20C). These results strongly suggest that PLB competes with Ca\(^{2+}\) for binding to the Ca\(^{2+}\)-ATPase, and that SERCA2a with PLB bound is catalytically inactive.
2. CONFIRMING COMPETITIVE BINDING OF PLB AND Ca\(^{2+}\) TO SERCA2a USING CATALYTICALLY INACTIVE D351A

The Ca\(^{2+}\) pump mutant D351A cannot hydrolyze ATP, but retains strong Ca\(^{2+}\) binding and maintains the Ca\(^{2+}\)-dependent equilibrium between \(E1\) and \(E2\). Like the wild-type enzyme, progressively higher concentrations of Ca\(^{2+}\) were required to dissociate the increasingly potent PLB mutants from D351A. Thus at each Ca\(^{2+}\) concentration tested, progressively more \(E2\cdot\text{PLB}\) was formed by the increasingly inhibitory PLB mutants, meaning that less \(E1\) was available for Ca\(^{2+}\) binding (Fig. 23D). Therefore, by stabilizing the enzyme in a Ca\(^{2+}\) free state, PLB decreases Ca\(^{2+}\) binding to the pump and alters the kinetics of enzyme activation by Ca\(^{2+}\).

The results shown here with the PLB supershifters and D351A unambiguously confirm that PLB decreases Ca\(^{2+}\) binding to SERCA2a, and provide very strong evidence for mutually exclusive binding of PLB and Ca\(^{2+}\) to the Ca\(^{2+}\) pump. In contrast to these results, several other groups have recently suggested that PLB binding to SERCA2a is unperturbed by Ca\(^{2+}\) binding (36, 37). These authors contend that localized structural changes in PLB, rather than complete dissociation of PLB from SERCA2a, account for the Ca\(^{2+}\)-induced inhibition of PLB cross-linking observed by our group (36, 37). However, PLB has been cross-linked to SERCA2a at numerous points of interaction located within both domains of PLB and two different regions of the Ca\(^{2+}\)-pump (6, 21-23), and in each case, PLB cross-linking was completely inhibited by micromolar Ca\(^{2+}\) concentration. Most importantly, in the work presented here we showed that higher concentrations of Ca\(^{2+}\) were required to inhibit cross-linking of the increasingly inhibitory PLB mutants to both D351A and wild-type SERCA2a (Figs. 20 and 23). Nevertheless, we accept the unlikely possibility that PLB does bind to the Ca\(^{2+}\) bound enzyme, but that PLB interactions with the enzyme in \(E1\) have not been detected by our cross-linking technique. However, we can conclude with certainty that if PLB does bind to the Ca\(^{2+}\)-bound enzyme, then the PLB binding site in \(E1\) is distinct from the inhibitory PLB binding site in \(E2\) described by our work, and one in which PLB does not effect Ca\(^{2+}\) pump activity.
3. THE EFFECTS OF PLB ON THE $V_{\text{max}}$ OF SERCA2a

According to our model PLB competes with Ca$^{2+}$ for binding to SERCA2a, therefore at saturating Ca$^{2+}$ concentration PLB should be completely dissociated from the Ca$^{2+}$ pump and have no effect on maximal enzyme activity. Here we showed that PLB molecules of normal inhibitory strength (N30C-PLB) do not significantly affect the $V_{\text{max}}$ of the Ca$^{2+}$-ATPase (Fig. 20). This result is contrary to conclusions of several recent studies in which PLB was reported to either decrease (44) or increase (42, 43, 45) the $V_{\text{max}}$ of the Ca$^{2+}$-ATPase. Using our viral constructs and the 2D12 antibody, Waggoner et al. (44) recently noted a modest reduction (~20%) in the $V_{\text{max}}$ of SERCA2a expressed alone compared to SERCA2a co-expressed with wild-type PLB. This is in disagreement with an earlier study in which no effect on $V_{\text{max}}$ was noted (64). We believe that the modest reduction in $V_{\text{max}}$ observed by Waggoner et al. (44) is more apparent than real. Fig. 20A points out that when Ca$^{2+}$-ATPase activities are carefully corrected for Ca$^{2+}$ pump expression levels, there is little or no inhibition of the enzyme at saturating Ca$^{2+}$ concentrations when SERCA2a is co-expressed with PLB mutants of normal inhibitory potency (N30C-PLB). Moreover, this relief of Ca$^{2+}$-ATPase inhibition at saturating Ca$^{2+}$ concentration is entirely consistent with the complete dissociation of N30C-PLB from SERCA2a observed at 1-2 µM Ca$^{2+}$ by chemical cross-linking (Fig. 20B). The studies in which wild-type PLB and some other PLB mutants were reported to actually increase the $V_{\text{max}}$ of the Ca$^{2+}$-ATPase were all conducted with the purified rabbit skeletal muscle enzyme co-reconstituted with purified PLB from detergent solution (42, 43, 45). In this case, it is possible that enzyme protection by PLB during the reconstitution process may have artifactually affected the results, as was recently suggested (45). Regardless, in multiple studies using cellular expression systems, no increase in $V_{\text{max}}$ by PLB has been noted (2, 3).

In contrast to N30C-PLB, the superinhibitory PLB mutants PLB3 and PLB4 did significantly reduce maximal enzyme activity measured at saturating Ca$^{2+}$ concentration (Fig. 20A). At Ca$^{2+}$ concentrations greater than 1-2 µM, the Ca$^{2+}$ pump loses significant activity due to back inhibition of the enzyme by Ca$^{2+}$ (58, 59). Ca$^{2+}$ concentrations in excess of 100 µM are required to dissociate PLB3 and PLB4 from SERCA2a, therefore the Ca$^{2+}$ pump co-expressed with PLB3 and PLB4 can never
achieve as high of a $V_{\text{max}}$ as the enzyme expressed alone or co-expressed with N30C-PLB. The effects of N30C-PLB and the PLB supershifters on maximal enzyme activity observed here are entirely consistent with the model of mutually exclusive binding of PLB and Ca$^{2+}$ as the mechanism of PLB regulation of SERCA2a.

4. THE PHYSIOLOGICAL EFFECTS OF PLB

The results shown here illustrate how wild-type PLB is perfectly poised to regulate cardiac contractile kinetics in intact myocardium, and may help to explain the detrimental effects of superinhibitory PLB on cardiac function observed in transgenic mouse models (29-31). Ca$^{2+}$ concentrations within the cardiomyocyte range from nanomolar to 1-2 μM (1), and the affinity of wild-type PLB for SERCA2a allows it to associate and dissociate from the enzyme over the same Ca$^{2+}$ concentration range at which contractile force develops. At low cytosolic Ca$^{2+}$ concentrations at which myofilament contractile force is low, the affinity of PLB for the Ca$^{2+}$-pump is high and enzyme inhibition by PLB is substantial, but still reversible by phosphorylation by protein kinase A (2, 3) or by the 2D12 antibody (5). At high Ca$^{2+}$ concentrations yielding peak contractile force, PLB is completely dissociated from the Ca$^{2+}$ pump and the enzyme is maximally active. However, for supershifting PLB mutants the situation is different. By virtue of their very high binding affinities for SERCA2a, the supershifters remain significantly bound to the Ca$^{2+}$ pump and continue to inhibit the enzyme at Ca$^{2+}$ concentrations that are normally saturating. At Ca$^{2+}$ concentrations high enough to dissociate these potent PLB molecules from the Ca$^{2+}$ pump (10-200 μM Ca$^{2+}$) (Fig. 20), significant back inhibition of the enzyme occurs. Thus, maximal Ca$^{2+}$-ATPase activity can never be realized when SERCA2a is co-expressed with potent PLB supershifters, even after phosphorylation of PLB by protein kinase A or after addition of the 2D12 antibody, both of which reduce the affinity of PLB for the Ca$^{2+}$ pump. Therefore, these results provide a mechanism to explain why transgenic mice overexpressing the most potent PLB supershifters develop cardiac hypertrophy, heart failure, and premature death (29-31).
5. STRUCTURAL CONSIDERATIONS: LONG DISTANCE COMMUNICATION BETWEEN THE Ca\textsuperscript{2+} BINDING SITES AND THE CATALYTIC SITE

Using PLB as a reporter molecule, we were able to estimate the Ca\textsuperscript{2+} and nucleotide binding affinities of D351A relative to wild-type SERCA2a, and make comparisons with previous determinations made for the skeletal muscle enzyme (SERCA1a). In an earlier study, MacIntosh et al. (55) used TNP-8N\textsubscript{3}-ATP photolabeling to measure the Ca\textsuperscript{2+} and ATP binding affinities of D351A (rabbit skeletal isoform) expressed in COS membranes. The authors found that relative to wild-type Ca\textsuperscript{2+}-ATPase, D351A had an extraordinarily high affinity for both Ca\textsuperscript{2+} (>10-fold increase) and ATP (20 - 100 fold increase) (55). They postulated that Ala substitution at Asp\textsuperscript{351} significantly increases the ATP affinity of the Ca\textsuperscript{2+}-ATPase by relieving electrostatic repulsion between the γ-phosphate of ATP and Asp\textsuperscript{351} of the wild-type enzyme. Moreover, they proposed that mutationally induced conformational changes at the site of ATP binding within the cytoplasmic head group were transmitted to the Ca\textsuperscript{2+} binding sites located at the membrane, substantially increasing the Ca\textsuperscript{2+} affinity of the enzyme. The very high ATP affinity of D351A, but not the high Ca\textsuperscript{2+} affinity, was confirmed in a subsequent study by Marchand et al. (56), also with SERCA1a. In this later report, ATP- and Ca\textsuperscript{2+}-binding affinities were determined for the purified enzyme in detergent solution.

Here, using PLB cross-linking to estimate Ca\textsuperscript{2+} affinity, we also noted an extremely high Ca\textsuperscript{2+} affinity for D351A, this time using the cardiac muscle isoform (SERCA2a). Our results indicate that D351A has a Ca\textsuperscript{2+} affinity at least 10 times higher than wild-type SERCA2a (Fig. 7A). This result is consistent with the earlier findings of MacIntosh et al. (55), but inconsistent with the results of Marchand et al. (56). It is well known that non-ionic detergents like C\textsubscript{12}E\textsubscript{8} and dodecy-maltoside substantially decrease the Ca\textsuperscript{2+}-binding affinity of SERCA pumps (65, 66), which may explain the failure of Marchand et al. to detect an increase in Ca\textsuperscript{2+} affinity for D351A (56).
Regarding ATP affinity, we determined a $K_d$ value of 9 $\mu$M for the wild-type enzyme, which is well within the range reported by other investigators for ATP binding at the low-affinity modulatory binding site of $E2$ measured in the absence of $Ca^{2+}$ (60-62). For D351A, we noted a modest 2.3-fold increase in ATP affinity relative to wild-type SERCA2a ($K_d = 4.0$ $\mu$M), in contrast to the two studies above which reported a much higher nucleotide binding affinity for D351A measured under similar conditions (55, 56). However, our results appear to be consistent with the recently determined crystal structure of the $E2(TG)$-AMPPCP complex, representing $E2$ with ATP bound at the modulatory site (20). According to this structure, ATP fits more loosely into the modulatory site (ATP binding site in $E2$) relative to the catalytic site. When ATP is bound to $E2$, the $\gamma$-phosphate is 9Å away from the phosphorylation site, making the electrostatic repulsion between the $\gamma$-phosphate and the negatively charged Asp$^{351}$ much less pronounced than what occurs when ATP is bound to $E1$ (20). Thus ATP affinity at the modulatory site may be less affected by the D351A mutation because the $\gamma$-phosphate of ATP does not interact closely with Asp$^{351}$ when ATP is bound here. Nevertheless, our results with D351A demonstrate that there is long-range communication between the catalytic site and the $Ca^{2+}$ binding sites, and removal of the negative charge at Asp$^{351}$ strikingly enhances the $Ca^{2+}$ binding affinity at the two $Ca^{2+}$ binding sites in the membrane.

**C. HYPOTHESIS 3: PLB BINDS EXCLUSIVELY TO THE $E2$-ATP CONFORMATION OF THE $Ca^{2+}$ PUMP**

Where in the catalytic cycle of SERCA2a does PLB act to slow or inhibit enzyme turnover? Mueller et al. (36) and Li et al. (37) have proposed that PLB acts at multiple kinetic steps in the $Ca^{2+}$-pump’s reaction cycle. Alternately, others have proposed that PLB acts at a single step, but there is disagreement with respect to which step. Tada et al. (39), Antipenko et al. (40) have suggested that PLB slows the rate of phosphoenzyme decomposition ($E2$-$P$ to $E2$-$P_i$ transition, see Fig. 4). Cantilina et al. (38) and Afara et al. (41) proposed that PLB blocks the conformational change that accompanies binding of the first $Ca^{2+}$ ion, facilitating
binding of the second. In contrast, we contend that PLB blocks the transition from $E2$ to $E1$, by stabilizing a single SERCA2a conformational state, $E2\cdot$ATP. An earlier kinetic study by our group (64) showed that PLB had no effect on either the rate the $E1\cdot$Ca to $E1'\cdot$Ca transition as proposed by Cantilina et al. (38) and Afara et al. (41), nor the rate of $E2\cdot$P to $E2\cdot$P$_i$ transition, as proposed by others (39, 40). Here, it was shown directly that PLB decreases Ca$^{2+}$ binding to $E1$ by stabilizing the enzyme in the Ca$^{2+}$-free $E2$ state, thereby decreasing the equilibrium constant for Ca$^{2+}$ binding. Moreover, using the effectors thapsigargin, vanadate, 2D12, and nucleotides (AMP, ADP, and ATP) we showed that PLB cross-linking was augmented substantially by ADP and ATP ($E2\cdot$ATP) (Fig. 25), but inhibited by thapsigargin ($E2\cdot$TG) (Fig. 24), vanadate (Fig. 26) and by binding of the 2D12 antibody to PLB (Fig. 21). These results support the hypothesis that PLB binds to the $E2\cdot$ATP conformation of SERCA2a and blocks the transition to $E1$.

1. **PLB BINDS TO DEPROTONATED $E2\cdot$ATP**

Early studies of the Ca$^{2+}$-ATPase showed that in the absence of Ca$^{2+}$, the intrinsic tryptophan fluorescence of SERCA was substantially increased by ATP and ADP, but was unaffected by AMP (60). This nucleotide-induced increase in fluorescence intensity was completely inhibited by TG, which was subsequently shown to reduce the affinity of the Ca$^{2+}$-ATPase for ATP through uncompetitive inhibition (61, 62). Similarly, PLB cross-linking to SERCA2a occurs in the absence of Ca$^{2+}$, is enhanced by ATP and ADP, but inhibited by TG (6, 21). Based upon these similarities, it was suggested that the physiological state detected by changes in fluorescence induced by nucleotide binding to $E2$ (60-62), is the unique $E2\cdot$ATP state that binds PLB (21).

In a recent study by Jensen et al. (20), it was suggested that TG stabilizes the fully protonated H$_nE2$ state of the Ca$^{2+}$ pump, and that ATP binding at the modulatory site stimulates deprotonation of $E2$, initiating the transition to $E1$. Here, using ATP stimulation of PLB cross-linking to measure ATP binding at different TG concentrations, we confirmed the ATP affinities of $E2$ and $E2\cdot$TG reported previously.
Moreover, we showed that ATP dramatically increases the resistance of the $E_2$-PLB complex to TG, shifting the $K_i$ values for TG inhibition of cross-linking by 100-200 fold for the supershifters PLB3 and PLB4 (Table 2). Thus, the PLB supershifters and ATP interact synergistically at $E_2$, stabilizing an $E_2$-ATP-PLB ternary complex that is remarkably resistant to TG. These results suggest that the $E_2$-ATP state detected by ATP-induced changes in Trp fluorescence (60-62) and by chemical cross-linking of PLB (6, 21), may be the deprotonated $E_2$-ATP state with ATP bound at the modulatory site. Moreover, TG may inhibit formation of this specific conformation, not by blocking ATP binding, but by hindering ATP stimulated deprotonation of the enzyme. Consistent with this interpretation, PLB does not bind to the $P_i$ (Fig. 12) or vanadate (Fig. 26) bound forms of the enzyme, both of which interact with protonated $H_nE_2$ state like TG (67). Also as observed with TG, ATP strongly enhances PLB cross-linking to SERCA2a in the presence of $P_i$ (Fig. 12) and vanadate (Fig. 26), being able to compete for $P_i$ (32) or vanadate binding (63, 68) to the Ca$^{2+}$-ATPase.

2. THE AFFINITY OF PLB FOR SERCA2a

Given TG’s reputation as an extremely potent, irreversible inhibitor of the Ca$^{2+}$-ATPase (34, 35), we were surprised to discover that TG did not disrupt the ternary complex between the PLB supershifters and $E_2$-ATP, even when membranes were pre-incubated for up to 1 hour with greater than stoichiometric concentrations of TG. Moreover, under these conditions favoring $E_2$-ATP, PLB3 and PLB4 bind even more tightly to SERCA2a than does TG, the highest affinity SERCA inhibitor identified to date (34, 35). Crystallographic studies have revealed that TG binds to $E_2$ in a cavity formed between transmembrane helices M3, M5, and M7, near the cytoplasmic membrane surface (18). This is on the opposite face of $E_2$ from the PLB binding site, which is predicted to extend along the groove formed between transmembrane helices M2, M4, and M9, based on cross-linking results (21, 22, 51). Our results suggest that binding of PLB at its site must drastically distort the TG binding pocket. Nonetheless, under enzyme turnover conditions, TG is the more
powerful SERCA inhibitor. In the presence of Ca$^{2+}$, catalytic activity is completely inhibited by TG through formation of a dead-end complex (34), whereas Ca$^{2+}$-ATPase inhibition by the PLB supershifters remains reversible, albeit at very high Ca$^{2+}$ concentrations (Fig. 20). It should be pointed out that TG binding to $E1\cdot Ca^{2+}$ as well as to $E2$ has been noted in many studies (20, 34, 69-71), and that the ability of TG to bind to different conformational states of SERCA may contribute to its apparently irreversible effect on Ca$^{2+}$-ATPase activity.

These results with TG indicate that the binding affinity of the PLB supershifters (PLB3 and PLB4) for $E2\cdot ATP$ measured in the absence of Ca$^{2+}$ is in the nanomolar range or lower. The affinities of the PLB mutants for SERCA2a were also estimated using the lower affinity Ca$^{2+}$-pump inhibitor vanadate, and the anti-PLB antibody, 2D12. Vanadate inhibits the Ca$^{2+}$-ATPase with micromolar affinity, and our cross-linking results indicated that N30C-PLB has an affinity for $E2\cdot ATP$ in the range of vanadate, whereas the affinities of PLB3 and PLB4 for SERCA2a are much greater. In addition, using 2D12 to estimate the binding affinities of the PLB mutants for SERCA2a in the absence of Ca$^{2+}$, we found that the affinity of PLB for the 2D12 antibody (0.1 μM) was similar to the affinity of N30C-PLB for Ca$^{2+}$-ATPase, but less than the affinity of the PLB supershifters for SERCA2a. Therefore, using effectors that act both on the Ca$^{2+}$-ATPase (TG and vanadate) and on PLB itself (2D12), we conclude that the affinity of PLB for the Ca$^{2+}$-pump is much greater than previously thought (51). In the absence of Ca$^{2+}$ and in the presence of ATP, N30C-PLB has an affinity for SERCA2a in the micromolar range, whereas PLB3 and PLB4 bind with nanomolar affinity or higher.

D. CONCLUSION AND FUTURE DIRECTIONS

The overall conclusion of this work is that PLB inhibits Ca$^{2+}$ binding to SERCA2a by stabilizing the enzyme in a Ca$^{2+}$-free $E2$ state. Clearly, PLB binding has long-range conformational effects on both the cytoplasmic domains and the transmembrane domain, and these effects are likely even more profound with the PLB supershifters. ATP binding to $E2$ accelerates the $E2$ to $E1\cdot Ca_2$ transition by
stimulating H+/Ca\(^{2+}\) cation exchange (20), while at the same time inducing structural changes that promote PLB binding. So, is the conformation of SERCA2a that binds to PLB really deprotonated E2-ATP, or Ca\(^{2+}\)-free E1 (62), or perhaps something in between (70)? Until the crystal structure of PLB-bound SERCA2a is determined we have no way of knowing. It was recently suggested that TG “rigidifies” the transmembrane domain of the Ca\(^{2+}\) pump, making it unresponsive to conformational changes occurring within the cytosolic domain (62). It is this ability of TG to fix the transmembrane helices that has enabled the Ca\(^{2+}\)-free, TG-bound enzyme to be crystallized, providing valuable structural information about the Ca\(^{2+}\)-ATPase in different E2 states (18). However, all of the E2 structures determined to date have been in the presence of irreversible inhibitors like TG or cyclopiazonic acid (72), and it is unclear how closely these inhibitor-bound structures resemble other, perhaps more physiological states of the enzyme (62). It is therefore our long-term goal to crystallize the Ca\(^{2+}\) pump complexed with PLB in order to provide a structure of E2 stabilized by a reversible inhibitor that is physiologically active in the heart. Here, we have shown that in the absence of Ca\(^{2+}\), the binding affinities of the supershifters are several fold higher than even TG, making the goal of crystallizing the Ca\(^{2+}\)-free enzyme stabilized by PLB3 or PLB4 seem plausible.
REFERENCES


23. Chen, Z., Akin, B.L., and Jones, L.R. 2010. Ca\textsuperscript{2+} binding to site I of the cardiac Ca\textsuperscript{2+} pump is sufficient to dissociate phospholamban. J. Biol. Chem. 285:3253-3260.


CURRICULUM VITAE

Brandy Lee Akin

CURRENT POSITION

Postdoctoral Research Fellow
Krannert Institute of Cardiology
Indiana University School of Medicine

EDUCATION

Bachelor of Science, 2003
Purdue University
Major: Biological Sciences
Minor: Chemistry

Doctor of Philosophy, 2010
Indiana University
Major: Biochemistry and Molecular Biology
Minor: Life Sciences
Dissertation: “Investigating the Molecular Mechanism of Phospholamban Regulation of the Cardiac Ca$^{2+}$ Pump of Sarcoplasmic Reticulum”

HONORS AND AWARDS

Jack Davis Award for Best Seminar by a Graduate Student 2005-2006, Department of Biochemistry and Molecular Biology, Indiana University School of Medicine

PROFESSIONAL SOCIETIES

Biophysical Society

LABORATORY EXPERIENCE

2001-2002 Volunteer Student Researcher for Dr. William Cooper, Department of Biology, Indiana University-Purdue University, Fort Wayne.

2003-2004 Research Technician for Dr. Larry Jones, Krannert Institute of Cardiology, Indiana University School of Medicine
POSTERS AND PRESENTATIONS


3. “Superinhibitory phospholamban mutants compete with Ca\(^{2+}\) for binding to SERCA2a” 2008. Poster presentation at Gordon Research Conference on Cardiac Regulatory Mechanisms, Colby-Sawyer College, New London, NH.


PUBLICATIONS


8. Chen, Z., Akin, B.L., and Jones, L.R. 2010. Ca\textsuperscript{2+} binding to site I of the cardiac Ca\textsuperscript{2+} pump is sufficient to dissociate phospholamban. *J. Biol. Chem.* 285:3253-3260.


**ABSTRACTS**


2. Chen, Z., **Akin, B.L.,** and Jones, L.R. 2007. Decreased binding of protein kinase A phosphorylated phospholamban (P-PLB) to the cardiac Ca\textsuperscript{2+} pump (SERCA2a) revealed by use of cross-linking reagents. *Biophys. J.* 8a.


6. Chen, Z., **Akin, B.L.,** and Jones, L.R. 2009. Ca\textsuperscript{2+} binding to site I of the cardiac Ca\textsuperscript{2+} pump (SERCA2a) is sufficient to dissociate phospholamban (PLB). *Biophys. J.* 210a-211a.